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 1  
Abbreviations 
 
 
aa  amino acid 
AC  adenylate cyclase 
ASA  accessible surface area 
AUC  analytical ultracentrifugation 
c-di-GMP bis-(3'-5')-cyclic guanosine monophosphate 
CD  circular dichroism 
DGC  diguanylate cyclase 
"  molar extinction coefficient 
GMPCPP 5'-guanylylmethylenebisphosphonate 
GTP  guanosine triphosphate 
GTP#S guanosine 5'-O-(1-thiotriphosphate) 
HK  histidine kinase 
HPt  histidine-containing phosphotransfer protein 
IP  primary inhibition site 
IS  secondary inhibition site 
ITC  isothermal titration calorimetry 
KD  dissociation constant 
kcat  turnover number, catalytic rate constant 
min  minute 
MR  molecular replacement 
MW  molecular weight 
NC  class III nucleotidyl cyclase 
NCS  non-crystallographic symmetry 
OD  optical density 
PDB  protein data bank 
PDE  phosphodiesterase 
POL  RNA/DNA polymerase 
RMSD  root mean square deviation 
rpm  revolutions per minute 
RU  response units 
Rec  response regulator receiver domain 
Abbreviations 
 2  
RR  response regulator 
s  second 
SE AUC sedimentation equilibrium analytical ultracentrifugation 
SEC-MALS size exclusion chromatography coupled multi angle light scattering 
SV AUC sedimentation velocity analytical ultracentrifugation 
SPR  surface plasmon resonance 
TCS  two-component system 
TM  melting temperature 
VM  matthews coefficient 
  3  
Abstract 
 
The ubiquitous bacterial second messenger bis-(3’-5’)-cycic di-guanosine 
monophosphate (c-di-GMP) turns out to be the key regulator of the antagonistic 
processes: motility of individual cells on the one hand and persistence of a bacterial 
population in biofilms on the other. The biosynthesis of c-di-GMP by consumption of 
two molecules GTP is performed by diguanylate cyclases (DGCs). DGCs consist of 
catalytic GGDEF domains in combination with a plethora of N-terminal, environment 
sensing regulatory domains. 
The previously elucidated crystal structure of the DGC PleD from C. crescentus has 
shown that the catalytic GGDEF domain shares its fold with the well studied 
adenylate cyclases and DNA polymerases. The ability of the GGDEF domain to bind 
only one GTP molecule requires formation of a complete joint-active site formed by 
two GGDEF domains. Therefore, DGCs have to form dimers to be enzymatically 
active. DGCs widely exploit environment-sensing domains for the regulation of their 
dimerization. In case of PleD, response regulator receiver domains (Rec1 and Rec2) 
are used for this process. 
Many DGCs are additionally regulated by allosteric product inhibition. The above 
mentioned crystal structure of PleD revealed binding of intercalated c-di-GMP dimers 
between a primary inhibition site (I-site), represented mainly by the conserved RxxD 
motif (GGDEF domain), and arginines of the secondary I-site (Rec2 domain). Two 
contradicting modes of action were proposed for this regulatory mechanism. (I) 
Inhibition by c-di-GMP binding to the RxxD motif inducing conformational changes 
in the active site. (II) Inhibition by c-di-GMP forming cross-links between the 
GGDEF and the Rec2 domains and preventing hereby the formation of the dimeric 
active site. 
In this study structural, biophysical and biochemical analysis of several DGCs from 
C. crescentus was undertaken, to elucidate the details of the regulatory mechanisms 
of this class of enzymes. 
Analysis of the so-called ‘stand-alone’ DGCs, which consist of 25-500 amino acids 
long segments in front of their GGDEF domains, has shown the inability of the 
GGDEF domains to form dimers autonomously. The ‘stand-alone’ DGCs utilize their 
N-terminal segments for dimerization. 
Abstract 
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To get insights in the environmental cues dependent regulatory mechanism of 
dimerization, the Rec domains bearing DGC PleD was crystallized in its 
pseudophosphorylated/activated form. The crystal structure of BeF3!•Mg
2+
 activated 
PleD is the first structure showing a full-length response regulator in its activated 
state. Comparison with the structure of non-activated PleD resulted in the elucidation 
of the molecular mechanisms of the dimerization process. Additionally, the formation 
of a two-fold symmetric, charged pocket at the (Rec1-Rec2)2 stem interface was 
observed, which might represent the long-sought ‘pole-localization’-signal for PleD. 
Besides giving insights in the substrate binding mode of the DGCs, the obtained 
structures shed light on the catalytic mechanism of DGCs. In combination with 
biochemical data the structures verified the ‘two-metal assisted’ catalysis mechanism 
for the DGCs. 
A new, c-di-GMP dimer dependent domain-cross-linking mode was revealed. It is 
generally applicable to DGCs, involving in the process merely the GGDEF domains. 
It turned out that the successful inhibition of the DGC PleD relies on the presence of 
primary- and secondary I-sites, whereas the initial binding of c-di-GMP depends 
solely on the primary I-site. PleD was shown to need R390 besides the RxxD motif 
(the whole I-site) to bind c-di-GMP. 
Finally, cross-linking of proteins by c-di-GMP, intradimeric like in PleD and 
intermolecularly like in DgcB, was shown and might represent the main regulatory 
function of this second messenger. 
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I INTRODUCTION 
 
Second messengers in bacteria 
In order to be able to respond appropriately to environmental cues, many organisms 
utilize the principle of second messenger dependent signal amplification in their 
signal transduction pathways. The interaction of the second messengers with their 
effectors, which are either a part of the target molecules or affect these, is able to 
promote a multitude of cellular answers on the protein, the DNA or the RNA levels. 
Similar to other kingdoms, Bacteria are known to utilize a multitude of nucleotide 
second messengers (1). Among them are the extensively studied cyclic AMP (cAMP) 
(2-4) and guanosine tetra/pentaphosphate ((p)ppGpp) (5,6), but also the recently 
discovered cyclic di-adenosine monophosphate (c-di-AMP) (7,8), the global role of 
which still has to be shown. 
Another member of this group, the bis-(3’-5’)-cyclic dimeric guanosine 
monophosphate (c-di-GMP), has only been recently recognized to play a crucial role 
in the multicellular behavior of bacteria (9-16). 
 
The ubiquitous bacterial second messenger c-di-GMP 
The first reports of the second messenger c-di-GMP date back to 1987, describing it 
as an allosteric activator of the cellulose synthase in Gluconacetobacter xylinus (17). 
Structural and biophysical studies on c-di-GMP (18,19) have revealed the high 
morphological complexity of this second messenger, which forms concentration and 
divalent-ion dependent intercalated structures. The low cellular concentrations of c-
di-GMP (20,21) in the low micro-molar range as well as its structures in complex 
with proteins (22-26) indicate that probably only the monomeric and the dimeric 
species are of physiological relevance. 
The same scientific group that discovered c-di-GMP was also able to identify the 
genes, which encode proteins involved in biosynthesis and breakdown of this second 
messenger (27). The catalysis of c-di-GMP by diguanylate cyclases (DGCs) 
consuming two molecules of GTP was assigned to the GGDEF domain, whereas 
degradation is performed by phosphodiesterases (PDEs) containing either the EAL or 
the HD-GYP domain. All three domains are actually named according to the 
consensus sequences in their active sites. 
I Introduction 
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The pivotal role of c-di-GMP as a global second messenger has not been realized 
until the onset of the genome sequencing times that showed broad phylogenetic 
distribution of DNA sequences encoding GGDEF, EAL and HD-GYP domain 
proteins (28). The complete absence of proteins bearing these domains in the 
kingdoms of Eukaryotes and Archaea and the ubiquitous presence in the eubacterial 
kingdom as well as the enormous magnitude of these proteins in almost each bacterial 
species woke a profound interest in c-di-GMP and in the related signal transduction 
pathway. Since then, giant scientific strides were made in recognition of the c-di-
GMP’s role in the regulation of cellular processes concerning the community 
behavior of bacteria. 
 
The role of c-di-GMP in bacterial pathogenesis: regulation of motility, biofilm 
formation and virulence gene expression 
Besides regulation of such processes as cell cycle control (29) or antibiotic production 
(30), c-di-GMP seems to control mainly the transition between the motile and the 
sessile ‘lifestyles’ in bacteria (9). Both bacterial states, the planctonic and the sessile 
(biofilm), are involved in the pathogenicity of these microorganisms. Motility is 
known to be a crucial factor in the early stage of the host infection (31,32). Biofilms, 
which are represented by complex microorganism communities embedded in an 
organic matrix, pose a high danger in the healthcare and the industrial sectors being 
highly resistant to antibiotics (33,34). The regulation of the cellular level of c-di-GMP 
by DGCs and PDEs enables the bacteria, harboring such pathogens as Vibrio 
cholerae, Yersinia pestis, Salmonella Typhimurium and Pseudomonas aeruginosa, to 
impede the inhibition of motility decreasing the concentration of c-di-GMP (35-37). 
On the other hand, raising the cellular concentration enables them to induce formation 
of the biofilm (38-40). 
Additionally, c-di-GMP was shown to be able to manipulate the expression of 
virulence factors (41,42). In order to understand the involvement of c-di-GMP in 
these pathogenic processes and to use this knowledge in the clinical intervention 
against the presented bacterial traits, the complex interaction between c-di-GMP and 
proteins involved in its synthesis, breakdown and transmission (effectors) has to be 
elucidated. 
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Controlled biosynthesis and degradation of c-di-GMP 
The identification of the enzymatic function of the GGDEF domain (previously 
named DUF1 = domain of unknown function) to produce one c-di-GMP and two 
pyrophosphate molecules using up two molecules GTP attracted the general scientific 
interest. The consensus sequence (GGDEF) was shown by mutagenesis to be a part of 
the active site (43,44). 
The overall fold of the GGDEF domains was first predicted by bioinformatics (45) 
and later on shown by X-ray crystallography (22) to be shared by adenylate cyclases 
(ACs) and DNA/RNA polymerases (POLs). The structure of the DGC PleD from C. 
crescentus has additionally shown that the GGDEF domains are restricted in binding 
a single GTP molecule. Therefore, formation of DGC dimers sharing a common 
active site formed at the interface of two GGDEF domains is the inevitable 
imperative for the enzymatic activity of DGCs. 
The detection of allosterically bound c-di-GMP dimers in the crystal structure of PleD 
and the subsequent biochemical analysis revealed the regulation of DGCs by non-
competitive product inhibition (22). The overall function of this regulatory process 
might be relevant for the concentration limitation of the enzymatic product and 
prevention of GTP depletion. Two distinct theories were postulated explaining the 
inhibitory mechanism. The first, the so-called “inhibition by domain immobilization”, 
claims a c-di-GMP dependent cross-linking of the catalytic GGDEF domain with the 
regulatory domains of the protein (22). In the structure of PleD the c-di-GMP dimers 
are found in interaction with R359xxD362 + R390 (= primary I-site) of the GGDEF 
domain and R148 + R178 of the regulatory domains (= secondary I-site). Another 
theory proposes a classical allosteric mechanism, by which the binding of c-di-GMP 
to the highly conserved R359xxD362 (RxxD motif) results in conformational changes 
in the active site (46). 
The EAL domain PDEs, which were shown to be active as monomers (24), linearize 
c-di-GMP to pGpG. Whether pGpG is acting as a second messenger is not known yet. 
The process of degradation was shown to be dependent on divalent cations. Mg
2+
 or 
Mn
2+
 are essential for the catalysis, whereas presence of Ca
2+
 or Zn
2+
 lead to 
inhibition (47-49). 
The second protein family of c-di-GMP degrading PDEs are the metal-dependent 
HD-GYP domain proteins, which are not related to the EAL domain proteins. These 
I Introduction 
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were shown to linearize c-di-GMP to pGpG and to be able to degrade the later ones to 
GMP molecules. 
One interesting class of the c-di-GMP processing proteins are the so-called “tandem-
proteins” composed of GGDEF and one of the PDE domains, EAL or HD-GYP. For 
the GGDEF-EAL domain protein PdeA from C. crescentus the PDE activity was 
shown, which can be modulated by GTP binding to the degenerated active site of the 
GGDEF domain (47). This speaks for GGDEF-EAL interdomain communication. In 
contrast to PdeA most “tandem-proteins” show no degeneration of the active sites, in 
neither of both domains. Insights in the regulatory mechanisms of these proteins will 
be the next step in the understanding of the c-di-GMP signal transduction pathway. 
One of the biggest riddles posed by the c-di-GMP signaling is the enormous number 
of GGDEF-, EAL- and HD-GYP domain proteins encoded by the genomes of 
bacteria. A single species can have up to 100 of such proteins, e.g. V. vulnificus (50). 
Such a high diversity of proteins having the same tasks, namely biosynthesis or 
degradation of c-di-GMP, stands for a highly sensitive signaling pathway, but also for 
the requirement of strict regulation. Most of the DGCs and PDEs utilize regulatory 
input domains at their N-terminus to do so. The high variability of these input 
modules, e.g. transmembrane domains, haem- or flavin associated PAS domains (51), 
light sensitive BLUF domains (52,53), small molecule binding GAF domains (54), 
response regulator receiver domains (Rec) of the ‘two-component’ system (22,23) 
and so on, seems to involve c-di-GMP signaling in sensing of a high number of 
environmental and cellular traits (50). 
Additionally, DGCs and PDEs that harbor Rec domains fusing the ‘two-component’ 
and the c-di-GMP signaling pathways indicate signal input in the c-di-GMP pools 
from ‘quorum sensing’ (1). 
 
Downstream effectors of c-di-GMP 
For a long time the molecular output activities of c-di-GMP have stayed hidden, but 
are now starting to emerge. One of the c-di-GMP binding effectors is known since the 
discovery of c-di-GMP, namely the cellulose synthase from G. xylinus (17). Inspired 
by this fact, computational analysis returned with a prediction of the so-called PilZ 
domain as a putative c-di-GMP effector (55). The genes encoding this domain are 
broadly distributed in bacteria. The domain is found in proteins in combination with 
several other domains as well as with GGDEF- and EAL domains. Binding of c-di-
I Introduction 
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GMP by PilZ domains was later on shown by biochemistry and structural biology 
(25,26,56). 
Prediction of another c-di-GMP effector was made on the basis of GGDEF domains 
possessing a degenerated active site, but an intact I-site (14). One of such proteins, 
PopA from C. crescentus, has recently been shown to target proteins for degradation 
in presence of c-di-GMP (29). The I-site motif of the DGCs seems also to be used 
independently of the GGDEF domain context. PelD of P.aeruginosa is activated by c-
di-GMP binding to a motif that is analog to the I-site motif of PleD (57). 
The targets of c-di-GMP are not exclusively proteins. This was recently shown by the 
interaction of the second messenger with riboswitches (58), targeting the translation 
of downstream effectors. 
Additionally, c-di-GMP might exert its second messenger effect by binding to or by 
forming protein complexes according to its cross-linking function in the DGC PleD 
(22). Further experiments have to show the biological relevance of this theory as well 
as to extend the characterization of the identified targets on molecular, biochemical 
and structural levels. 
 
Aims of this work 
The analysis of the DGCs shed light not only on the c-di-GMP biosynthesis, but also 
on its regulatory mechanisms as well as on c-di-GMP effectors (see above). On the 
other hand, several questions stayed unanswered. 
The regulation of DGCs by their N-terminal input domains was predicted to depend 
on environmental cues and to result in dimerization of these DGCs. The best 
understood model DGC is PleD consisting of two N-terminal Rec domains, a 
phosphorylatable Rec1 and a non-phosphorylatable Rec2, as input domains. The 
phosphorylation of Rec1 by its cognate histidine-kinases PleC and DivJ results in 
dimerization of PleD (43,59,60) and subsequent sequestration to the stalked pole of 
the microorganism. Since PleD was crystallized in the non-phosphorylated state, it 
would be beneficial to gain the structure of the activated protein to understand the 
molecular mechanism of the dimerization process as well as the function of the non-
phosphorylatable Rec2. 
The structure of the DGC PleD was solved in complex with its product c-di-GMP 
bound not only to the allosteric sites, but also to the active site (22). The scientists 
proposed a catalytic mechanism, where E371 of the GGDEF sequence motif plays the 
I Introduction 
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role of the general base in the process of the phosphodiester-bond formation. This 
mechanism is distinct from the one utilized by the structurally related ACs and POLs, 
which utilize the ‘two-metal assisted’ catalysis. To test the postulated mechanism as 
well as to understand how DGCs manage to perform both phosphodiester-bond-
formations simultaneously to create the macrocycle of c-di-GMP, the DGC PleD was 
tried to be trapped crystallographically in the productive state. 
The identification of the allosteric binding site of c-di-GMP in DGCs was a crucial 
step in the identification of c-di-GMP effectors (see above), but it is still unclear 
which of the two proposed allosteric mechanisms is utilized by the DGCs and what 
are the molecular and kinetic properties of this process. 
Although the GGDEF domain proteins were shown to be active as dimers, it is not 
clear whether these domains are able to dimerize autonomously. Several DGCs are 
identified to consist of an unassigned N-terminal segment ranging from 20 to 500 
amino acids besides the C-terminal GGDEF domains. Are such ‘stand-alone’ DGCs 
enzymatically active? And if yes, how do they dimerize and get input from their 
environment? 
I have tried to answer these questions during my PhD work using structural, 
biophysical and biochemical techniques presenting the results in the following 
sections. Chapter II.1 and II.2 are dealing with the structures of activated PleD 
concentrating on the mechanisms of the Rec domain dependent dimerization of PleD, 
the DGC catalysis and the allosteric product inhibition. Chapter II.3 presents the 
analysis of the allosteric product inhibition mechanism by the means of biochemical 
and biophysical techniques. Chapter II.4 describes the characterization of the ‘stand-
alone’ DGCs, DgcA and DgcB from C. crescentus. 
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SUMMARY
Cyclic di-guanosinemonophosphate (c-di-GMP)
is a ubiquitous bacterial second messenger
involved in the regulation of cell surface-asso-
ciated traits and persistence. We have deter-
mined the crystal structure of PleD from Caulo-
bacter crescentus, a response regulator with
a diguanylate cyclase (DGC) domain, in its acti-
vated form. The BeF3
! modification of its re-
ceiver domain causes rearrangement with re-
spect to an adaptor domain, which, in turn,
promotes dimer formation, allowing for the effi-
cient encounter of two symmetric catalytic do-
mains. The substrate analog GTPaS and two
putative cations are bound to the active sites
in a manner similar to adenylate cyclases, sug-
gestingananalogous two-metal catalyticmech-
anism. An allosteric c-di-GMP-binding mode
that crosslinks DGC and an adaptor domain
had been identified before. Here, a second
mode is observed that crosslinks the DGC do-
mains within a PleD dimer. Both modes cause
noncompetitive product inhibition by domain
immobilization.
INTRODUCTION
The central role of bis-(30/ 50)-cyclic di-guanosinemono-
phosphate (c-di-GMP) as a signaling molecule has been
realized only upon the recent recognition of the omnipres-
ence of genes coding for diguanylate cyclase domains
(DGC or GGDEF domains) in bacterial genomes. C-di-
GMP regulates cell surface-associated traits and commu-
nity behavior such as biofilm formation in most eubacteria
(Jenal and Malone, 2006), and its relevance to the viru-
lence of pathogenic bacteria has been demonstrated
(Tischler and Camilli, 2004). In particular, the dinucleotide
has been proposed to orchestrate the switch between
acute and persistent phases of infection (Malone et al.,
2007). C-di-GMP is synthesized out of two molecules of
GTP and is degraded into the linear dinucleotide pGpG
by the opposing activities of DGCs and c-di-GMP-specific
phosphodiesterases. Both enzymes occur in combina-
tions with various other, mostly sensory or regulatory, do-
mains. It is believed that in this way environmental or inter-
nal stimuli can control the production of c-di-GMP, which,
in turn, will affect downstream targets (Jenal and Malone,
2006). One of these c-di-GMP effector domains (PilZ) has
recently been identified (Amikam and Galperin, 2006;
Christen et al., 2007).
About 10% of the known DGCs are response regulators
(RRs) as part of two-component systems (Jenal and
Malone, 2006). RRs are activated by cognate histidine
kinases that phosphorylate a conserved aspartate of the
receiver domain (Rec) (Stock et al., 2000). Various Rec do-
mains have been studied in great detail, and the structural
changes upon activation have been described (for a re-
view, see Robinson et al., 2000).
Due to the instability of the aspartyl phosphoanhydride,
these studies have been performed with phosphoryl ana-
logs. Notably, modification of CheY by beryllium fluoride
(BeF3
!) (Lee et al., 2001) resulted in structural changes
fully equivalent to those obtained by phosphorylation
(Birck et al., 1999; Lewis et al., 1999). Upon activation,
a Thr/Ser side chain is pulled toward the modified aspar-
tate, and a Phe/Tyr side chain follows to fill the gap and
changes from a semiexposed to a buried position. Con-
comitantly, mainly the b4-a4 loop of the Rec domain is
changing its conformation. Much less is known about
how these conformational changes elicited in the Rec do-
main are signaled downstream either to target proteins or
to the output domain of full-length RRs. The structures of
full-length CheB (Djordjevic et al., 1998), NarL (Maris et al.,
2002), PrrA (Nowak et al., 2006), and members of the
OmpR/PhoB subfamily (DrrB, DrrD) (Robinson et al., 2003)
have been determined, but only in the nonactivated state.
Distinct mechanisms of activation have been proposed,
such as relief of active site obstruction (e.g., CheB) (Djord-
jevic et al., 1998) (PrrA) (Nowak et al., 2006), dimer or olig-
omer formation (e.g., PhoB) (Bachhawat et al., 2005), or
both (NarL) (Maris et al., 2002).
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PleD from Caulobacter crescentus is an unorthodox
RR consisting of a Rec domain (D1) with the phosphorylat-
able aspartate, a Rec-like adaptor domain (D2), and the
enzymatic DGC domain, also called the GGDEF domain
according to a conserved sequence motif. The protein is
intimately involved in the transition of the Caulobacter
cells from the motile to the sessile form (Aldridge et al.,
2003). To gain insight into the molecular mechanisms of
catalysis and regulation exerted by DGCs, we have previ-
ously determined the crystal structure of PleD (Chan et al.,
2004) (Figures 2A and 2C). The fold of DGC (PFAM00990;
http://www.sanger.ac.uk/Software/Pfam/) closely resem-
bles that of class III nucleotidyl cyclases, which include
bacterial and eukaryotic adenylyl cyclases (ACs) (Chan
et al., 2004). A recent review with a detailed comparison
of DGC and AC has been published recently (Sinha and
Sprang, 2006).
Enzymatic studies showed that pseudo phosphoryla-
tion of PleD by BeF3
! results in a 35-fold increase of spe-
cific activity (R.P. et al., unpublished data). The nonacti-
vated structure of PleD (Chan et al., 2004) suggests that
this activation may occur via dimerization of the D1/D2
stem domains, which brings two DGC domains into prox-
imity as a prerequisite for the condensation reaction to
occur (‘‘activation by dimerization’’). At the same time, the
structure showed that the c-di-GMP product crosslinks
the DGC with the adaptor domain, suggesting, together
with biochemical data, that the product allosterically in-
hibits the enzyme by hampering the productive encounter
of the twoDGCdomains of the dimer (‘‘inhibition by immo-
bilization’’). Later, the central role in feedback inhibition of
the allosteric-binding site on the DGCdomain (with a char-
acteristic RxxD sequence motif) was demonstrated by
mutagenesis, genetic screens, and sequence compari-
son, and an alternative allosteric model for the inhibition
mechanism was proposed (Christen et al., 2006).
Here, we present the crystal structure of PleD after
modification of the active aspartate with the phosphoryl
analog BeF3
! and compare it with the nonactivated struc-
ture (Chan et al., 2004). Themodification induces a change
in the relative arrangement of the two Rec domains within
the monomer, resulting in the stabilization of the dimer
that is the catalytically competent form (R.P. et al., unpub-
lished data). Details about the binding mode of the sub-
strate analog GTPaS/Mg2+ are elucidated, and possible
catalytic mechanisms are discussed. Unexpectedly, a
new, to our knowledge, and possibly general mode of
noncompetitive product inhibition for DGCs in which
c-di-GMP immobilizes the two DGC domains of the PleD
dimer in a nonproductive arrangement is revealed.
RESULTS
Dimerization in Solution
Size-exclusion chromatography gave evidence that non-
activated PleD partly dimerizes in a concentration-depen-
dent manner at high protein concentrations (Figure 1A).
Most relevant, dimerization was enhanced by the addition
of BeF3
! and divalent cations (Mg2+ or Mn2+) (Figure 1B),
and the manganese cation was shown to be more effi-
cient. In parallel, BeF3
!-induced dimerization has also
been shown via chemical crosslinking, and it was shown
that the dimeric fraction entirely contains the catalytic
activity (R.P. et al., unpublished data).
To thermodynamically quantify the dimerization affinity,
isothermal titration calorimetry (ITC) was performed. Fig-
ure 1C shows the heat peaks measured after injections
of predominantly dimerized PleD into matching buffer; in
the beginning of the titration, the dilution of the titrant is
largest and causes the dissociation of the dimers. Since
dimerization is exothermic in this case, heat is consumed
for dissociation after each injection. With increasing con-
centration in the cell, more and more dimers persist, and
the heat of dissociation decreases gradually. Figure 1D
illustrates two pairs of such data sets obtained by normal-
ization and baseline (Qdil) correction of ITC curves with
activated and nonactivated protein, respectively, on a log-
arithmic scale. Qdil ranged from "1 kcal/mol for the non-
activated PleD mutant to !6 and !3 kcal/mol for the acti-
vated protein, and they include dilution effects and slight
pH or temperature mismatches of titrant and cell content.
At first glance, it is seen that the activated protein dimer-
izes at a much lower concentration. Upon activation with
BeF3
!, the fitted dissociation constant, KD, of dimerization
decreased from about 100 mM to < 10 mM. Hereby, the lat-
ter value represents an upper limit, because, for this kind
of experiment, the instrument was close to the detection
limit. The enthalpy of dimerization is !10 kcal/mol for the
nonactivated protein and is apparently somewhat less
exothermic for the activated protein, suggesting that acti-
vation eliminates an entropic hindrance of dimerization.
Structural Changes Induced by Activation
To obtain the structure of activated PleD, crystallization
was attempted with BeF3
!-modified protein. Crystals
were obtained upon addition of c-di-GMP, which had
been shown earlier to rigidify the multidomain protein by
crosslinking an allosteric site of the DGC domain with
a neighboring domain (Chan et al., 2004) and the substrate
analog GTPaS/Mg2+ (Table 1). The pseudo phosphoryla-
tion at Asp53 in domain D1 resulted in a train of structural
changes (Figures 2 and 3), ultimately leading to a dramatic
tightening of the dimer interface of the (D1/D2)2 stem com-
pared to the nonactivated structure (Figure 2). Further-
more, but probably not as a consequence of activation,
the arrangement of the DGC domains is drastically differ-
ent from the nonactivated structure.
Asp53 of Rec domain D1 appears fully modified (Figures
3A and 3B) and closely resembles phospho-aspartate
(Lewis et al., 1999), with a Be-O distance of 1.58 A˚ (re-
strained in refinement to 1.55 A˚) and a Cg-Od-Be-F1 dihe-
dral cis conformation. The moiety forms four H bonds with
the binding pocket and contributes to the coordination
of the adjacent Mg2+ ion. The modification results in a re-
structuring of the b4-a4 loop, with Thr83 moving by more
than 3 A˚ relative to the position in the nonactivated state to
form an H bond with the BeF3
! moiety (Figures 3A and
3B). The vacated space, in turn, is claimed by Phe102,
Structure
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which changes its side chain conformation from gauche+
to trans to become buried; part of the b5 main chain (res-
idues 102–104) moves up to 2 A˚.
Domain D1 interacts closely and in a pseudo two-fold
symmetric manner with the adaptor domain D2 across
the a4-b5-a5 faces of both domains. Activation results
in a domain rotation/shift of 14#/6 A˚ of D2 relative to D1
and a massive repacking of the domain interface (Fig-
ure 3A). In Figures 3C and 3D, the D1/D2 interface is dis-
played in its two states. While most of the contacting D1
residues stay in touch with the D2 domain, Arg91, Val110,
and Ile251 contribute to the interface only in the nonacti-
vated state, and residues Arg88, Ile92, Leu95, Val241,
Gln259, and Ala263 contribute only in the activated state.
Amazingly, the three interdomain salt bridges (Asp108-
Arg237, Arg115-Asp250, Asp101-Arg264) are not disrup-
ted during the transition, although the partners move up to
7 A˚ with respect to each other. However, upon activation,
Asp257 swaps its ion-pair partner Arg91 for Arg88. Upon
activation, the hydrophobic contact patch aroundMet111,
Ala114, Met240, and Leu244 becomes repacked, and an
additional apolar contact is formed that involves Ile92,
Leu95, and Ala263 (Figures 3C and 3D).
On the quaternary level, in both crystal structures, the
Rec and the adaptor domains form a dyad symmetric
(D1/D2)2 ‘‘stem’’ with the equivalent domains of a second
monomer (Figure 2). Since both domains contribute to the
interchain interface, it is obvious that the relative reposi-
tioning of the domains within each chain also has conse-
quences on the quaternary structure. The weak dimer in-
terface observed in the nonactivated structure (Chan
et al., 2004) is greatly tightened upon activation (Figures
2C and 2D), and the buried accessible surface areas per
monomer (DASA) increased from 900 A˚2 to 1436 A˚2.
In both states, the interchain contacts between D1 and
D2 are formed in an isologous, i.e., two-fold symmetric
manner. In the nonactivated structure, there is only a small
contact patch around Tyr26 resulting in a discontinuous
Figure 1. Size-Exclusion Chromatography Elution Profiles and Isothermal Titration Calorimetry of Purified PleD Mutant R313A
(A–D) This mutant with unmodified dimerization domains had been chosen for technical reasons (availability of material). (A) Elution profiles of
nonactivated PleD at a protein concentration of 33 mM (gray) and 66 mM (black). (B) Elution profiles of BeF3
!-modified PleD (66 mM) in presence of
10 mM MgCl2 (gray) and 1 mM MnCl2 (black). Note that c-di-GMP is released and separated from the protein during the runs. (C) The primary ITC
data for a dilution experiment (initial PleD concentration = 0.86 mM) with nonactivated PleD. (D) The integrated two ITC data sets for the activated
(solid symbols) and nonactivated (open symbols) PleD mutant, after subtraction of the baseline heats, Qdil, obtained by model-based extrapolation
of the curves to high concentrations. The curves illustrate the best fits with shared KD values of 100 mM (nonactivated) and 10 mM (activated). Due to
the noisy data, the latter value represents an upper limit.
Structure 15, 915–927, August 2007 ª2007 Elsevier Ltd All rights reserved 917
Structure
Structure of Activated PleD
interface (Figure 4A). While this contact is maintained in
the activated structure, a multitude of additional interac-
tions are formed involving the a1, b2, b3, a5 face of D1
and the a3, a3-b3, a5 face of D2 (Figure 4B). Three salt
bridges are formed between the subunits, and there is a
sulfate ion on the two-fold symmetry axis at the center
of a basic cluster formed by Arg117 and Arg121 with their
symmetry mates (Figure 4B). In addition, there are a few
polar interactions and a small hydrophobic cluster formed
by Leu124 and Val125 and their symmetry mates.
Upon activation, the a5 helices of the stem domains be-
come extended by 4–5 residues at the C terminus. It is
these helices that experience the largest change in relative
interchain distance, moving from a closest distance of
about 10 A˚ to direct van der Waals contact (Figures 4A
and 4B). Together with their symmetry mates, the C-termi-
nal thirdsof the foura5helices formaparallelahelix bundle
in the dimer (Figure 2B).
Active Site
To gain further insight into the catalytic action of DGCs,
the substrate analog GTPaS and Mg2+ had been added
to the crystallization set-ups. In the activated structure,
both active sites of the DGC domains, which face away
from each other (see below), are occupied by the ligands.
Figure 5 shows that the b- and g-phosphates are tightly
bound and form two H bonds to main chain amides of
the short P loop between strand b1 and helix a1 and ionic
interactions to Lys442, Arg446, and a putative Mg2+ ion
(named metal B in analogy to the situation in adenylate
cyclases [Tesmer et al., 1999]). The cation is additionally
coordinated bymain chain carbonyl 328of theP loop, both
carboxylate oxygens of Asp327, and Glu370, OE1. In one
subunit of the dimer (subunit A), a second putative Mg2+
ion (metal A) is bound from another side to the same two
side chains, interacting with atoms Asp327, OD2 and
Glu370, OE2, respectively. Consistent with the structure,
mutation of Asp327 to Ala resulted in a complete loss of
enzymatic activity, as has been seen previously for mutant
E370Q (Christen et al., 2006). The elongated density of the
omit map (Figure 5) and the elevated B factor of the ion (52
A˚2) possibly indicate alternative positions for this ion. Nei-
ther the a-thiophosphate nor the ribose moiety are bound
to the protein by specific interactions, resulting in compar-
atively high B values ("60 A˚2). The guanine moiety, in con-
trast, is well adopted, forming H bonds with Asn335 and
Asp344 of the guanine-binding pocket, also already iden-
tified in the nonactivated protein-product complex (Chan
et al., 2004).
Allosteric Product Binding
Compared to the previously determined nonactivated
structure of PleD, the DGC domains adopt a drastically
different position with respect to the stem domains. While,
in the previous structure, the weak D2/DGC interface is
strengthened by a bound c-di-GMP dimer that effectively
crosslinks the domains (Figure 2A), in the present struc-
ture, this interface is completely disrupted and the DGC
domains are swung out to form a two-fold symmetric c-di-
GMP-crosslinked dimer (Figure 6). The difference in the
relative orientation of the DGC domain with respect to the
stem is probably not a direct consequence of Rec modifi-
cation, since, assuming a flexible D2-DGC linker, a change
of the crosslinking mode appears to be structurally feasi-
ble in either state. Thus, both domain organizations would
occur in thermodynamic equilibrium in solution.
C-di-GMP forms dimers with the four guanyl bases
stacked and intercalated as in small-molecule crystals
(Egli et al., 1990; Liaw et al., 1990). Figure 6B shows that
this form is found bound to the allosteric site. Two guanyl
bases interact with DGC residues Arg359, Asp362, and
Arg390 (primary I site, Ip), whereas the neighboring third
base is bonded to Arg313 of the adjacent DGC domain
(secondary I site, IS,DGC). Due to symmetry, there are two
isologous crosslinks within the DGC dimer (Figure 6). The
dimer interface (with a DASA of 517 A˚2 that increases to
1044 A˚2 upon ligand binding) is exclusively hydrophobic
and involves Ala360, Ile361, Pro377, and the hydrophobic
part of the Ser309 side chain. Noteworthy, in the nonacti-
vated structure, a c-di-GMP dimer is bound to Ip in exactly
the same way, but it crosslinks with the third base and a
phosphate moiety to Arg148 and Arg178 of the D2 domain
(IS,D2).
Table 1. Data Collection and Refinement Statistics of
Activated PleD in Complex with c-di-GMP and GTPaS
Data Collection
Space group P21212
Cell dimensions
a, b, c (A˚) 128.9, 132.6, 88.4
Resolution (A˚) 30–2.71 (2.85–2.71)
Rmerge (%) 9.8 (43.6)
I/s(I) 10.2 (1.9)
Completeness (%) 95.0 (78.0)
Redundancy 2.9 (2.4)
Refinement
Number of reflections 39,043
Rwork/Rfree 21.7/25.4
Number of atoms
Protein 7,012
Ligands 272
Water 14
B factors (A˚2)
Protein 41.0
Ligands 43.7
Water 29.2
Rmsds
Bond lengths (A˚) 0.011
Bond angles (#) 1.5
Data in parentheses belong to the outer resolution shell.
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Feedback Inhibition Probed by Mutagenesis
PleD shows noncompetitive product inhibition with a Ki of
about 0.5 mM (Chan et al., 2004) (Table 2). Crosslinking of
the DGC domain to the D2 domain, as seen in the crystal
structure of nonactivated PleD, has been proposed to be
the mechanism of product inhibition in PleD, since this
would prevent the productive encounter of the two GTP-
loaded enzyme domains (Chan et al., 2004). To test the
‘‘inhibition by domain immobilization’’ hypothesis, perti-
nent PleD mutants have been analyzed recently (Christen
et al., 2006). Mutations of primary I site (Ip) residues were,
apart fromR390A, largely deleterious for activity and, thus,
inconclusive. Mutation R390A, however, showed a con-
siderably increased Ki. Truncation of the secondary I site
residues on D2 (Is,D2; mutant R148A/R178A), on the other
hand, did not affect feedback inhibition.
Here, we applied a photometric pyrophosphate assay
to reinvestigate this Is,D2 mutant and to probe the role of
the secondary Is,DGC site (Arg313). As can be seen from
Table 2, mutating the Is,D2 or the Is,DGC site alone had a
Figure 2. Ribbon Diagrams of the Dimeric Crystal Structures of Nonactivated PleD and BeF3
!-Activated PleD
(A–D) In (A) and (B) the view is perpendicular to the two-fold axis of the stem. In (C) and (D), the view is rotated by 90# around a horizontal axis with
respect to the top panels, showing the bottom view of the (D1/D2)2 stem with the DGC domains in the rear clipped off for clarity. The domains are
colored in red (Rec domain D1), yellow (adaptor domain D2), and green (enzymatic domain DGC, with the GGEEF signature motif highlighted in
blue). The disordered parts of the interdomain linkers are shown in gray. Labels with a prime indicate symmetry-related elements. The two-fold sym-
metry axes are shown as thin, straight lines. (A andC) Nonactivated PleD (Chan et al., 2004) is associated to a loose dimer. The active sites (A sites) are
occupied by c-di-GMP, which crosslinks to an adjacent dimer (not shown). Intercalated (c-di-GMP)2 dimers are bound to allosteric inhibition sites I
and I0. Each inhibition site is comprised of a primary inhibition site on DGC (Ip; Arg359, Asp362, Arg390) and a secondary site on the adaptor domain
(Is,D2 ;R148, R178). (B and D) In the activated structure, the phosphorylation site (P site) is modified by BeF3
! and Mg2+, and the active site (A site)
harbors GTPaS/Mg2+. (C-di-GMP)2 dimers are bound to the dyad-related sites I and I0. Each site is comprised of the primary Ip site, as in the non-
activated structure, and a secondary I site of the symmetry-related DGC (Is,DGC; R313; also see Figure 6). The two A sites face in opposite directions,
rendering the enzyme catalytically incompetent.
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Figure 3. Structural Changes Invoked by BeF3
! Modification of Asp53
(A) Comparison of the Ca traces of the D1/D2 PleD stem in its activated (D1, red; D2, yellow) and nonactivated (gray) conformation after superposition
of the D1 domains. Residues of the acidic pocket as well as Thr83 and Phe102 are shown in full.
(B) Blow-up of the superimposed D1 domains around the activation site; residues involved in pseudo phosphorylation are shown in full. The omit map
for Asp53-BeF3
! and the associated Mg2+ ion is depicted at 3a.
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moderate effect on the inhibition constants, with a 10-fold
and 2-fold increase, respectively. Our values deviate
slightly from those measured by Christen et al. (2006) for
wild-type and R148A/R178A PleD, possibly because their
data had been measured by a different technique (thin-
layer chromatography). Furthermore, the published Ki
values were actually IC50 values. Truncating both second-
ary I sites in the triple mutant R148A/R178A/R313A in-
creased the Ki by more than 60-fold. Interestingly, it was
not possible to inhibit this mutant completely, with the
inhibited state showing a residual kcat0 rate constant of
about 5%of kcat (Table 2; Figure S2D, see the Supplemen-
tal Data available with this article online). All mutants, but
in particular those involving Is,D2 residues, showed consid-
erably elevated activity (Table 2). This may be due to a
decreased dimerization KD of the nonactivated mutant
proteins.
The KD of c-di-GMP binding to the triple mutant is about
4 mM (ITC measurement, data not shown) and, thus, is in-
creased by only a factor of about 10 with respect to PleD
wild-type (R.P. et al., unpublished data). This affinity most
probably is due to c-di-GMP binding to the uncompro-
mised Ip site. In summary, the data indicate that the two
immobilization modes operate redundantly, i.e., the integ-
rity of only one of the Is sites is required for noncompetitive
product inhibition, presumably via domain crosslinking.
DISCUSSION
DGCs play a central role in bacterial c-di-GMP signaling.
Therefore, their action, synthesis of the secondary mes-
senger, must be tightly controlled (Christen et al., 2006).
Comparison of the structures of nonactivated and acti-
vated PleD allows us to propose the mechanisms of acti-
vation by phosphorylation and, unexpectedly, suggests
two redundant modes of feedback inhibition. For a sche-
matic overview of the various structural states of PleD,
see Figure 7. Furthermore, the binding mode of the sub-
strate analog GTPaS gives insight into the catalytic mech-
anism of the cyclization reaction.
Activation
It has recently become apparent that BeF3-modified Rec
domains of RR transcription factors of the OmpR/PhoB
family form two-fold symmetric homodimers (Bachhawat
et al., 2005; Toro-Roman et al., 2005a, 2005b). Since their
DNA-binding domains bind cooperatively to their target
sequences, it was suggested that protein dimerization is
the mechanism of activation. In some cases, the active
dimer structure was also seen in crystals of the native pro-
tein (Toro-Roman et al., 2005a, 2005b), which may, how-
ever, be of no physiological relevance considering the
high protein concentration needed for crystallization.
In PleD, the signal generated by pseudo phosphoryla-
tion of Asp53 is transduced to the a4-b5-a5 face, where
it promotes the D1/D2 rearrangement, which, in turn, facil-
itates dimerization. As in other Rec domains, the con-
served Phe/Tyr at the center of this interface follows the
movement of a Thr/Ser and changes its rotameric state.
Themovement of Phe102 is compensated by a slight twist
of the C terminus of helix a4, allowing residues Ile92 and
Leu95 to make apolar interdomain contacts with Ala263.
Together with other rather subtle differences at the a4-
b5-a5 face of D1 a substantial domain rearrangement is
induced (Figure 3A). It is unlikely that these rearrange-
ments are caused by crystal packing, since, in the loosely
(C and D) Close-up view of the D1/D2 interface in the (C) nonactivated and (D) activated state showing the quasi-two-fold symmetric interface. Both
domains contribute their a4-b5-a5 face. The viewing direction is along the quasi-dyad. All residues of the D1/D2 interface aswell as Thr83 and Phe102
are shown in stick and sphere representation for polar and apolar residues, respectively. Residues, which do not interact in one state, but do so in the
other, are shown in white.
Figure 4. Intermonomer D1/D20 Contact before and after
Activation
(A andB) In the dimeric stem, all shown contacts occur twice due to the
two-fold symmetry. Interface residues are shown in full. (A) In nonacti-
vated PleD, the interaction is restricted to a small contact patch around
Tyr26. In (B) activated PleD, there is a multitude of polar and ionic
interactions and an apolar contact between Leu124, Val125 (green
spheres,) and the corresponding residues of the symmetry-related
D10 (not shown). A putative sulfate ion is found on the symmetry axis
crosslinking Ag117 and Arg121 with their symmetry mates.
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packed crystals (VM = 3.8 A˚
3/Da), the crystal contact areas
are more than 2-fold smaller than the dimer interface.
Interestingly, the two PleDRec domains of a given chain
interact quasi-two-fold symmetrically and in a very similar
way as what is observed for the homodimerization of Rec
domains of the OmpR/PhoB subfamily. While the a4-b5-
a5 face is the interaction surface in both cases, the similar-
ity even extends to the residue level. In PleD, Asp101/
Arg115 and Asp250/Arg264 form two quasi-isologous
interdomain salt bridges at the center of the interface (Fig-
ures 3C and 3D), whereas homologous residues form
isologous interchain salt bridges in the Rec domains of the
OmpR/PhoB family (e.g., Asp99/Arg113 for ArcA) (Toro-
Roman et al., 2005a).
DGCs catalyze the condensation of two identical sub-
strates (GTP) to form the two-fold symmetric c-di-GMP
product. Since the DGC domain binds only one substrate,
two such domains are needed for catalysis, as depicted
in the mechanistic model of Figure 7 (state 4). Control of
dimerization allows for simple and efficient regulation of
the catalytic activity, as the reaction type for the encounter
of substrate-loaded DGC domains is changed from bi- to
unimolecular. At the high protein concentration of 20 mM
used in the enzymatic assays (Table 2), dimerization of
nonactivated PleD with a KD of about 100 mM is not negli-
gible, explaining the observed constitutive activity. The
physiological PleD concentration is not known and may
vary within the cell. But, clearly, activation by reduction of
the dissociation constant, KD, will bemost effective at pro-
tein concentrations well below the KD of nonactivated
PleD. Indeed, it has been shown that, at a lower protein
concentration of 5 mM, the catalytic rate is enhanced by
a factor of 35 upon BeF3
! modification, and that it is the
dimeric species that carries the activity (R.P. et al., unpub-
lished data).
For WspR from Pseudomonaas fluorescens, which is a
DGC with a single N-terminal Rec domain, a more indirect
dimerization mechanism, with phosphorylation relieving
the dimer interface obstruction caused by the effector do-
main, has been proposed (Malone et al., 2007). For RRp1
from Borrelia burgdorferi, which has the same Rec-DGC
domain organization, phosphorylation-dependent cyclase
activity has been demonstrated (Ryjenkov et al., 2005).
Thus, in these cases, a second Rec-like domain such as
the adaptor domain of PleD appears to be dispensible
for dimerization, and it may serve an additional regulatory
function in RRs with a Rec-Rec-DGC domain composition
(see below). How DGCs without Rec domains are acti-
vated remains to be investigated. Several of them may be
constitutive dimers such as DgcA (CC3285) from C. cres-
centus with its putative N-terminal coiled-coil domain
(P.W., unpublished data).
Catalysis
The active site of the DGC domain of PleD is identified by
the bound substrate analog GTPaS. It consists of well-
defined subsites for the b- and g-phosphates and for the
guanine base (Figure 5), which explains the observed sub-
strate specificity (Chan et al., 2004; Paul et al., 2004). The
structural similarity of the DGC domain to adenylate cy-
clase (AC) and DNA polymerase (POL) has been pointed
out (Chan et al., 2004). From this work, it is apparent
that the similarity also extends to the mode of substrate
binding as far as the position of the terminal phosphates
close to the P loop, the presence of metal B, and its coor-
dination by the phosphates and two invariant carboxylates
(D327 and E370 in PleD) are concerned. Metal site A is
also occupied in one of the subunits (Figure 5), but the
a-phosphate is not in coordinating distance as in the bac-
terial AC CyaC (Steegborn et al., 2005) and in POL
Figure 5. Substrate Analog GTPaS and Mg2+ Bound to the Active Site of PleD
The omit map for the ligands is contoured at 3s. The DGC domain is shown in ribbon representation; the GGEEF signature hairpin is shown in dark
blue, and all interacting residues and the P loop main chain (residues 328–331) are shown in full. (c-di-GMP)2 bound to the Ip site of the DGC domain
can be seen in the rear.
922 Structure 15, 915–927, August 2007 ª2007 Elsevier Ltd All rights reserved
Structure
Structure of Activated PleD
(Doublie et al., 1998). This may be caused by the thiol
modification of the ligand or the absence of the second
substrate. Modeling shows that moderate torsional ad-
justments can bring the a-phosphate in coordinating dis-
tance tometal A, with an orientation ready for in-line attack
onto the Pa-Pb diester bond. This can occur without
compromising binding of the terminal phosphates or the
guanine.
The role of the conserved Glu371 in DGCs (Figure S1)
has not been clarified, but it may coordinate metal A tran-
siently and/or serve as a proton acceptor for the incoming
30-hydroxyl of the other subunit. Indeed, mutagenesis has
shown that Glu371 is as indispensable for catalysis as are
the magnesium ligands Glu370 (Christen et al., 2006) and
Asp327 (data not shown). Another conserved residue in
the active site is Lys332, whose side chain amino group
can easily adopt a position from which it could stabilize
the charge of the pentavalent phosphoryl transition state
and the pyrophosphate leaving group (Figure S1). The
same role has been postulated for the nonhomologous
Arg1150 in CyaC (Steegborn et al., 2005).
To form the catalytically competent enzyme-substrate
complex (Michaelis-Menten complex), two substrate-
loaded DGC domains have to line-up in antiparallel orien-
tation, such that the 30-hydroxyl groups of the bound sub-
strates are brought in close proximity to the a-phosphate
of the other GTP molecule and such that they are properly
positioned to perform an intermolecular in-line nucleo-
philic attack onto Pa from the side opposing the suscepti-
ble Pa-Pb diester bond. Modeling shows that this can
be achieved without clashes in a dimeric arrangement, in
which helix a4 of one domain contacts the small b sheet
(b0, b00) of the symmetry-related domain (Figure S1). The
interface carries a number of ionic side chains that proba-
bly are involved in intermolecular salt bridges. The model
of the (DGC)2-c-di-GMP product complex obtained after
only minor rearrangements of the reactive groups (Fig-
ure S1B) is different from that observed experimentally
in nonactivated PleD (Chan et al., 2004), where c-di-GMP
crosslinks A sites of adjacent dimers. This is due to a differ-
ence in the position of the ribose and a-phosphate moie-
ties relative to the protein, whereas the guanine base is
bound in the same way. The orientation of the product
in the active site of nonactivated PleD is most probably
enforced by the artifactual, ligand-mediated dimer-dimer
association in the crystal.
The close resemblance of the constellation of reactive
groups and metal ions in the modeled PleD Michaelis-
Menten complexwith that in ACandPOL suggests that the
same two-metal-assisted mechanism for phosphodiester
formation as suggested for ACs (Tesmer et al., 1999) and
for POLs (Steitz, 1999) is operational in DGCs. More ki-
netic and mutagenesis experiments have to be performed
to reveal the precise catalytic mechanism of DGCs.
Feedback Inhibition
DGCs exhibit exquisite noncompetitive product inhibition,
as demonstrated biochemically for PleD (Chan et al.,
2004; Paul et al., 2004) and for DgcA from C. crescentus
Figure 6. Crosslinking of the DGC Domains by c-di-GMP
(A) Ribbon diagram of the DGC dimer along its symmetry axis; both
(c-di-GMP)2 ligands and interacting residues are shown in full. The
(c-di-GMP)2 ligands are bound to the I site (IP site and the Is,DGC site
of the adjacent subunit).
(B) Close-up view of the intercalated (c-di-GMP)2 ligand, which cross-
links the two DGC domains (dark- and light-green surface representa-
tion) by binding to the Ip (Arg359, Asp362, Arg390) and the Is,DGC
(R3130) site of the adjacent domain.
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(Christen et al., 2006), and, based on conserved Ip sites,
this is expected to be the case for the majority of DGC do-
mains (Christen et al., 2006). Feedback inhibition prevents
futile GTP consumption and probably defines an upper
ceiling for the concentration of the second messenger c-
di-GMP in the bacterial cell. Christen et al. (2006) showed
that the allosteric Ip site is crucial for binding and product
inhibition and suggested that communication between the
Table 2. Kinetic Data of Nonactivated Wild-Type and Mutant PleD
Wild-type PleD PleD R148A/R178A PleD R313A PleD R148A/R178A/R313A
IC50 (mM) 7 ± 2 17 ± 4 9 ± 2 30 ± 5
Ki (mM) 0.5
a 5 0.9 33
Ks (mM) 26 20
a 21 25
kcat (mM c-di-GMP/[s $ mM PleD]) 9.0 $ 10
!4 1.5 $ 10!2 4.0 $ 10!3 1.6 $ 10!2
kcat
0 (mM c-di-GMP/[s $ mM PleD]) 0a 0a 0a 8.1 $ 10!4
IC50 values represent experimental values with estimated standard deviations based on twomeasurements at GTP concentrations
of 100 mM and 500 mM. The concentration of the protein was 20 mM. The other kinetic parameters have been obtained by fitting
numerical simulations to the time course of c-di-GMP concentration at various inhibitory concentrations (Figure S2). In the simple
kinetic scheme, enzyme and substrate as well as enzyme and product are in thermodynamic equilibrium, with dissociation con-
stants of Ks and Ki, respectively, with the product binding noncompetitively to an allosteric site. Also, product and substrate binding
are assumed to be independent of each other. kcat and kcat0 are the catalytic rate constants of substrate turnover for noninhibited
and inhibited protein, respectively. The fitted values for the on-rate constants of substrate and product ranged between 100 s!1 and
350 s!1. It should be noted that the fits for PleD wild-type andmutant R148A/R178A were poor (Figures S2A and S2B), and, hence,
the corresponding parameters not very well determined. This may be due to the simplicity of the kinetic model.
a Parameter was fixed in simulation.
Figure 7. Mechanistic Model of PleD Regulation
The model is adapted from Chan et al. (2004). The DGC domain (green) is connected via a flexible linker to the stem (receiver domain D1 [red] and
adaptor domain D2 [yellow]) and is supposed to be mobile relative to it. (Upper row) Activation. Phosphorylation of domain D1 leads to a rearrange-
ment of the stem domains, which, in turn, allows for formation of a tight dimeric stem (3). The dimeric arrangement is a prerequisite for an efficient and
productive encounter of the two substrate-loaded DGC domains to form the c-di-GMP product (4). (Lower row) Product inhibition. Dimeric product
molecules, (c-di-GMP)2, can crosslink the primary inhibition site onDGC, Ip, with a secondary binding site either on D2, Is,D2 (5) or on the adjacent DGC
domain, Is,DGC (6). The former structure has been observed experimentally with nonactivated PleD (Chan et al., 2004), the latter structure is presented
in this report. In both cases, the DGC domains become immobilized, and the active sites are hampered from a productive encounter. Note that a
possible direct communication between Ip and A sites (Christen et al., 2006) is not depicted.
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Ip site and the active site of a DGC domain could cause the
observed noncompetitive product inhibition. However, in
the nonactivated structure (Chan et al., 2004), the enzy-
matic product in the form of two intercalated c-di-GMP
molecules was found to crosslink the Ip with the Is,D2 site
on the adjacent D2 domain (Figure 7, state 5). Therefore,
an ‘‘inhibition by domain immobilization’’ mechanism, in
which domain crosslinking by c-di-GMP would prevent
productive encounter of the two enzymatic domains of
the dimer, was proposed. Indeed, (c-di-GMP)2 can be re-
garded as a multivalent ligand that offers, among other
features, theO6-N7 edges of its four guanyl bases for spe-
cific pairing with arginine guanidyl groups, as observed in
DNA-protein interactions. In nonactivated PleD, the ligand
crosslinks the well-defined and well-conserved (Christen
et al., 2006) Ip site on the a2-b2 corner of DGC (formed
by Arg359, Asp362, Arg392) with arginines 148 and 178
of D2 (Is,D2).
In the present structure, a similar mechanism can be
deduced. In this mechanism, the dimeric ligand is again
bound to the Ip site, but its other valency crosslinks to a
hitherto unrecognized, to our knowledge, secondary site
on the adjacent DGC domain of the dimer (Is,DGC). As a re-
sult, the DGC domains interact in a nonproductive manner
with the two A sites, which point away from each other
(Figure 2B). Our functional analysis of pertinent mutants
(Table 2) suggests that domain immobilization might in-
deed contribute to feedback regulation, and that the two
inhibition modes operate redundantly (Figure 7, states 5
and 6). The advantage of redundancy in this context is
not clear, but we note that efficient DGC-DGC crosslinking
obviously can operate only after dimerization, while D2-
DGC crosslinking occurs within the nonactivated mono-
mer. Why the triple mutant is not fully active upon c-di-
GMP binding, but rather switches to a slower rate (Table
2), remains to be investigated. This may be due to the
residual binding capacity of the mutated Is sites, the exis-
tence of additional Is sites with low affinity, or a change of
active site structure and/or dynamics upon allosteric
product binding to the Ip site, as suggested by molecular
simulations (Christen et al., 2006).
The relevance of feedback inhibition has been dis-
cussed before upon recognizing that the R359xxD362 motif
of the Ip site is largely conserved (Christen et al., 2006). It is
present in 59% of all GGDEF domain sequences of the
current PFAM release (5200 sequences) that have an in-
tact GGD(E)EF motif and are, therefore, putative DGCs.
A large part of these seem to operate via c-di-GMP cross-
linking of Ip with an Is,DGC site, as observed in the present
PleD structure. This can be inferred from the fact that 64%
of the DGC sequences with the RxxD motif show an argi-
nine at position 313 of helix a0 or at a position one turn of
the helix farther up (positions 316 and 317), fromwhere the
long side chain probably could also reach the ligand. Co-
variation calculations show a significant correlation of 0.45
(0.32, 0.61) for simultaneously finding the RxxD motif and
an arginine at position 313 (316, 317). Of the subset of
19 DGCs for which guanylate cyclase activity has been
shown experimentally (see Figure S4 in Christen et al.
[2006]), 14 display the RxxD motif of the Ip site, and all
but one display an arginine residue at one of the second-
ary positions.
This implies that catalytic domain immobilization by
DGC-DGC crosslinking is a rather common feedback inhi-
bition mechanism of DGCs and does not rely on second-
ary inhibition sites on other domains. This autonomy of the
DGCdomain has probably been an advantage in evolution
to conserve feedback inhibition. Interestingly, feedback
inhibition is also observed in the prototype of a ‘‘single-
domain’’ DGC, DgcA from C. crescentus, whose se-
quence exhibits both Ip and Is,DGC sites as well as a small
N-terminal extension of possibly coiled-coil structure for
dimerization (Christen et al., 2006).
The multivalency of the second messenger c-di-GMP
appears perfectly suited for signal transfer. Here, we
showed evidence that it can be utilized for domain cross-
linking, which elicits large structural changes and which
may well also work for downstream signaling processes.
Interestingly, c-di-GMP binds to the N terminus of the
PilZ effector domain (Christen et al., 2007), i.e., to a strate-
gic position where it could control domain arrangement in
multidomain targets carrying this domain. The identifica-
tion of additional c-di-GMP effector proteins will reveal
to what extent this notion can be generalized.
EXPERIMENTAL PROCEDURES
Mutagenesis, Expression, and Purification
PleD mutations, D327A, R313A and R148A/R178A/R313A, were per-
formed by using the QuickChange II Site-Directed Mutagenesis Kit
(Stratagene) based on pRUN plasmids (derived from the pBR322
vector) containing the C-terminally His6-tagged wild-type gene (Chan
et al., 2004) or the R148A/R178A double mutant (Christen et al.,
2006). C-terminally His6-tagged full-length PleD and mutants were ex-
pressed in the E. coli BL21(DE3)pLysS strain, induced by 0.5 mM IPTG
(3–4 hr, 30#C). Cells were washed twice with 20 mM Tris-HCl (pH 8.0),
500 mM NaCl buffer and were stored at !80#C. The proteins were
purified by affinity chromatography with 5 ml HisTrap columns (GE
Healthcare) and "200 mM imidazole for elution. The pooled protein
fractions were concentrated and further purified by size-exclusion
(SEC) chromatography by using the Superdex 200 HR 26/60 column
(GE Healthcare) and 20 mM Tris-HCL (pH 8.0), 100 mM NaCl as run-
ning buffer (SEC buffer). For this step, the protein concentration was
kept low (5–10 mg/ml) to ensure dissociation and removal of bound
c-diGMP. The protein was concentrated to 10 mg/ml, aliquoted, and
stored at !20#C for further use.
Activation of PleD by BeF3
- Modification
Activation of PleDwas accomplished by supplementing the SEC buffer
with BeCl2, NaF, and either MgCl2 or MnCl2 (A buffer). Final concentra-
tions were 200 mM for PleD, 1 mM for BeCl2, 10 mM for NaF, 10mM for
MgCl2, and 1 mM for MnCl2. The protein was incubated for at least
30 min before experiments were conducted.
C-di-GMP
Pure samples of c-di-GMP were obtained from N. Amiot, Department
of Chemistry, University of Basel. It was chemically synthesized
according to procedures by Amiot et al. (2006).
Enzymatic Assays
DGC activity of wild-type andmutant PleDwas analyzed bymonitoring
the production of pyrophosphate by using a pyrophosphatase-cou-
pled spectrophotometric assay. Details are given elsewhere (Chan
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et al., 2004). The kinetic data were fitted to numerical simulations of
a scheme of noncompetitive product inhibition by using the program
Berkeley Madonna.
Analytical Size-Exclusion Chromatography
Dimerization of PleD was monitored by size-exclusion chromatogra-
phy (SEC) by using a Superdex 200 HR 10/30 column (GE Healthcare).
SEC and A buffers were used as running buffers for nonactivated and
activated protein samples, respectively. Runs were performed on an
A¨KTApurifier (GE Healthcare) system at a flow rate of 0.7 ml/min.
The concentrations of the eluted peak fractions were measured by
an online refractometer (Optilab rEX, Wyatt Technology).
Isothermal Titration Calorimetry
Samples of the PleD mutant protein R313A were first diluted 15-fold
either in SEC or A buffer (containing Mn2+ as divalent cation) and
then concentrated by using a 15 ml Amicon Ultra MWCO 10 kDa (Milli-
pore) concentrator. Protein samples and buffers were degassed (Ther-
moVac,MicroCal) at 2# below the temperature used in the experiments
before loading into the VP-isothermal titration calorimetry (ITC) (Micro-
cal, Northampton, MA). Details of the ITCmeasurement procedure and
analysis of self-association have been described previously (McPhail
and Cooper, 1997; Velazquez-Campoy et al., 2004). In short, 10 ml
samples of nonactivated (two experiments at concentrations 929 mM
and 861 mM) and activated (108 mM and 99 mM) PleD were injected
into the cell filled with buffer (1.4 ml volume) at 6 min intervals. The
measurements of nonactivated and activated protein were performed
at 15#C and at 10#C, respectively. Both measurements of each state
were fit together to obtain global DH and KD values. A constant back-
ground heat, produced by the dilution of the titrant, residual differ-
ences in the buffer composition in syringe and cell, and technical ef-
fects was eliminated by allowing for a constant heat contribution
(Qdil) as another fit parameter upon data evaluation.
Crystallography
Crystallization of activated PleD was performed at room temperature
by the hanging-drop vapor-diffusion technique. Before crystallization,
c-di-GMP and Rp-GTP-a-S (BioLog) were added with final concentra-
tions of 0.2 mM and 1mM, respectively, to BeF3
!/Mg2+-modified PleD
samples (final concentration 100 mM). A (1 ml + 1 ml) mixture of protein
and well solution (0.1 M HEPES [pH 8.0], 0.73 M Na2SO4) gave rise to
crystals of needle shape. Diffraction data were collected from a single
crystal at the Swiss Light Source, Paul-Scherrer-Institute, Villigen,
Switzerland, and were processed with MOSFLM/SCALA (CCP4,
1994). Orientations and positions of individual domains were deter-
mined by molecular replacement with the structure of nonactivated
PleD (PDB code 1W25) by using PHASER (McCoy, 2007). The model
was built by using COOT (Emsley and Cowtan, 2004) and was refined
with REFMAC (CCP4, 1994). Two-fold NCS restraints were imposed.
Supplemental Data
Supplemental data include a figure of the modeled structure of the
competent PleD-substrate complex, a figure of the PleD-product
complex and a figure with the kinetic data of wild-type and mutant
PleD and are available at http://www.structure.org/cgi/content/full/
15/8/915/DC1/.
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  Figure S1.  Model of the Catalytically Competent Dimer Constellation of Diguanylate Cyclase 
Ribbon diagram with active site residues and ligands shown in full.  (A) Michaelis-Menten complex 
with a GTP molecule bound to each active site. (B) Complex of the enzyme with the products c-di-
GMP and pyrophosphate after intermolecular phosphodiester formation between 3’ hydroxyl and P!. 
Note the steric hindrance between the two products. Since the pyrophosphate molecules are tightly 
bound, it is probable that the c-di-GMP product will change its orientation in the binding site prior to 
dissociation. The Michaelis-Menten model is based on the GTP!S - PleD complex structure (Fig. 4), 
with the !-phosphate rotated manually into coordinating distance to metal A. The two DGC domains 
are approximately 2-fold symmetric with the symmetry axis (viewing direction) running through the 
center of the bound c-di-GMP in panel (B). 
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Figure S2. Time Course of c-di-GMP Production at Various c-di-GMP Concentrations 
Panels A, B, and C show the data for wild-type PleD and PleD mutants R148A/R178A, R313A, 
R148A/R178A/R313A, respectively. The symbols indicate the experimental values obtained with a 
spectrophotometric assay that measures the production of pyrophosphate, the second product of the 
DGC reaction 2 GTP -> c-di-GMP + 2 PPi (see Material and Methods of main text). The protein con-
centration was 20 µM, the GTP substrate concentration 100 µM. The thin lines show simulated values 
based on a simple kinetic model (panel E) of non-competitive product inhibition assuming independ-
ence of substrate and product binding. The resulting parameters are given in Table 2 of the main text. 
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Abstract 
We report the crystal structure of BeF3¯ -activated diguanylate cyclase PleD with the 
product c-di-GMP bound to one of the active sites and to the allosteric inhibition 
sites. PleD consists of two tandem response regulator receiver domains and a C-
terminal GGDEF domain. The activated PleD dimers form a charged pocket on the 
molecular dyad of the (Rec1-Rec2)2 stem. This binding pocket turns out to be a 
feature of Rec1-Rec2-GGDEF proteins.  
Diguanylate cyclases, in contrast to nucleotidyl cyclases and DNA/RNA 
polymerases, form simultaneously two phosphodiester bonds utilizing the ‘two-metal 
assisted’ catalysis. The main question concerning this reaction is – how do the 
diguanylate cyclases manage to ensure the precision of the enzymatic reactions. We 
have analyzed the catalysis relevant features of the diguanylate cyclase PleD on its 
structural level and propose a catalytic mechanism for this family of proteins.
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Introduction 
 
Eubacteria, archaea and some eukaryotic classes utilize the ‘two-component system’ 
(TCS) signal transduction pathway to regulate their response to environmental traits 
(1,2). The archaic TCS consist of a transmembrane histidine kinase (HK) sensing the 
environmental stimuli, and a cytosolic response regulator (RR) responsible for the 
cellular response. Stimulus recognition by HK results in autophosphorylation of a 
conserved histidine residue in the so called H-box of the dimerization domain and in 
subsequent transfer of the high-energetic phosphoryl group to a conserved aspartate 
of the receiver domain (Rec) of RRs (3-5). 
Several organisms use the more elaborated phosphorelay version of TSC, containing 
additionally a histidine-containing phosphotransfer (HPt) protein that shuttles 
phosphoryl groups between Rec domains (6,7). Evolutionary and structural analysis 
of HPts shows partly higher similarity to the HK dimerization domains than between 
proteins of the HPt class (7-9). Crystallization of HPts in complex with Rec domains 
of their cognate RRs has revealed the mechanisms of selectivity and phosphoryl 
group transfer between HKs and RRs (7,9). 
Phosphorylation of Rec domains induces subtle structural changes (for details see 
reviews (3,5)) resulting in activation of RR’s effector domains. Although several 
activation mechanisms are described (10-12), in many cases activation leads to 
dimerization of Rec domains (13,14). 
High exploitation of the TCSs by bacteria can be observed in freshwater bacterium C. 
crescentus, possessing 44 different RRs (2,15). One of these RRs is PleD (16). PleD 
is involved in pole morphogenesis during the dimorphic cell division of C. crescentus 
producing flagellated swarmer and a holdfast bearing cells (17-19). Upon 
phosphorylation by its cognate HKs PleC and DivJ (20-22) PleD is sequestered to the 
stalked pole (20). It could be shown that dimerization and not activation is the 
imperative for shuttling to the pole (23). Unfortunately, neither the recruiting partner 
of PleD at the pole, nor the pole localization signal, which is coded by dimeric PleD, 
are known.  
PleD consists besides the N-terminal phosphorylatable Rec1 and the non-functional 
Rec2 domain, which form in activated state the two-fold symmetric (Rec1-Rec2)2 
‘stem’, of a C-terminal GGDEF effector domain (13,24). GGDEF domains have been 
shown to possess the diguanylate cyclase (DGC) activity and to produce the novel 
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second messenger c-di-GMP out of two GTP molecules (20,25). According to its 
cellular concentration, c-di-GMP is involved in environment-sensing and multi-
cellular communication processes like sessility and motility, biofilm formation and 
synthesis of virulence factors in hosts (26-29).  
GGDEF domains have been predicted (30) to utilize the same ferredoxin-like 
structural fold as monocyclic nucleotidyl cyclases (NC) and RNA/DNA polymerases 
(POL). This was subsequently verified by the crystal structure analysis of non-
activated PleD (denoted as PleD-na throughout this paper) (24). Moreover the recent 
crystal structure of activated PleD in complex with substrate analoge GTPS and two 
putative Mg2+-ions (denoted as PleD-act1 throughout this paper) (13) demonstrate, 
that all three protein classes utilize the two-metal assisted catalysis mechanism (31). 
The nucleophilic in-line attack of (deoxy-) ribose 3’-hydroxyl group at P and release 
of P via a SN2 (bimolecular nucleophilic substitution) mechanism is supported by 
two Mg2+-ions. Mg2+-ion (B) stabilizes the phosphates of the bound substrate as well 
as the intermediate pentacovalent coordinated P (31). Mg2+-ion (A), besides 
stabilizing P, activates the attacking 3’-hydroxyl group by lowering its pKA value 
either directly or through a mediating water molecule (31). Both metal ions are 
coordinated by the carboxyl groups of two acidic residues, which are highly 
conserved in all three protein clades (32). Despite performing a single phosphodiester 
forming reaction similarly to NCs and POLs, DGCs have the task to perform two 
such reactions simultaneously. Capability of a single GGDEF domain to bind only a 
single GTP molecule, as was shown by PleD crystal structures (13,24), results in 
utilization of a more sophisticated catalytic mechanism by DGCs. As to produce c-di-
GMP catalytically, GGDEF domains have to form perfectly aligned dimers (23). 
Here, we present the crystal structure of BeF3¯ -activated PleD in complex with an 
active site bound c-di-GMP molecule (PleD-act2). We have compared this structure 
with other DGC, as well as NC and POL structures, aiming to answer the following 
questions. What function does the non-phosphorylatable Rec2 domain exert in the 
DGC PleD, being dispensable for dimerization in other Rec-GGDEF domain proteins 
(50)? How do the DGCs prevent monocyclization of GTP to cGMP, a reaction 
performed by NCs, having all necessary residues for this reaction in a single GGDEF 
domain? Concerning the precision of the DGCs in the process of the product 
biosynthesis – how do DGCs manage to carry out both cyclization reactions 
simultaneously, avoiding generation of product intermediates? And last but not least, 
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which role might the highly conserved, but functionally unassigned but indispensable 
glutamate 371 of the GGDEF signature motif play in c-di-GMP synthesis? 
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Materials and Methods 
 
Expression and Purification 
Expression and purification of C-terminally His6-tagged wild-type and R148A 
R178A R313A PleD as well as wild-type DgcB (Uniprot entry: Q9A776) constructs 
were performed as described previously (13). Removal of bound c-di-GMP was 
accomplished by performing an additional size-exclusion chromatography (SEC) run 
using Superdex 200 HR26/60 column (GE Healthcare), 20 mM Tris-HCl (pH 8.0), 
100 mM NaCl as running buffer and protein at low concentration (< 5 mg/ml). 
Activation procedure of PleD by BeF3¯ •Mg2+ is described elsewhere (13). 
 
Crystallography 
Prior to crystallization of activated PleD, c-di-GMP and GMPCPP (Jena Bioscience) 
were added with final concentrations of 0.2 mM and 2 mM, respectively. 
Crystallization of BeF3¯ •Mg2+ activated PleD was described previously (13). Single 
crystal derived diffraction data was processed with MOSFLM/SCALA(33). The 
crystal structure was determined by molecular replacement using the program 
PHASER (34) and the structure of PleD-act1 (PDB code 2v0n) as template. Model 
building and refinement was performed with COOT (35) and REFMAC (33), 
imposing two-fold NCS restraints. 
 
Enzymology 
Enzymatic activity of PleD in presence of sulfate and phosphate was measured at a 
protein concentration of 40 µM in a 50 mM Tris-HCl pH 8.0, 10 mM MgCl2 buffer. 
PleD was activated adding 1 mM BeCl2 and 10 mM NaF. Effects of sulfate and 
phosphate were measured at standard conditions adding sodium salts of both anions 
to a final concentration of 5 mM. Reactions were started by addition of 6.7 mM GTP 
and incubated for 20 minutes at room temperature. Detection of produced c-di-GMP 
was detected by the FPLC method (see below). 
Enzymatic activity of DgcB in presence of divalent cations was performed at a 
protein concentration of 29.5 µM in a 50 mM Tris-HCl pH 8.0 buffer. Manganese or 
magnesium was added to enzymatic reactions at 0.1, 0.5, 1, 5 and 10 mM final-
concentrations, respectively. Effect of calcium, that was used at same concentrations, 
was measured in presence of 2 mM Mg2+. Reactions were started adding 0.5 mM 
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GTP and were incubated for 1 hour at room temperature prior to inactivation and 
detection by FPLC method. 
 
Quantification of c-di-GMP levels  
Quantification of c-di-GMP amount, produced by DgcB, PleD wild-type and R148A 
R178A R313A mutant, was performed by FPLC-anion exchange chromatography 
(36). In short, enzymatic reactions were stopped by denaturating the protein at 95° C 
for 1 minute. Heated samples were filtered (Ultrafree-MC, 0.22 µm, Millipore), 
diluted 1:10 in a 5 mM NH4HCO3 solution (= running buffer) to an end-volume of 1 
ml and applied to a 1 ml Resource Q anion exchange column using an ÄKTA Purifier 
FPLC machine (GE Healthcare). Elution was carried out with a 5 to 1000 mM 
NH4HCO3 gradient. Nucleotides were eluted as well separated peaks applying a 
shallow gradient of the elution buffer, resulting in identification of GDP, GTP and c-
di-GMP nucleotides at distinct positions, respectively. Identity of these nucleotides 
was verified by comparison to elution profiles of nucleotide standards and by ESI-
TOF MS. UV-peak areas of c-di-GMP standards at different concentrations were used 
for standard curve creation for quantification of c-di-GMP. 
 
HPLC-ESI TOF MS analysis 
Prior to mass spectrometry the FPLC peak fractions were lyophilized in a SpeedVac 
(ThermoScientific) and resolubilized in 150 µl 20 mM ammoniumacetate pH 6.4, that 
was used as running buffer to avoid GTP degradation. Nucleotide mass detection was 
performed on a micrOTOF (Bruker Daltonics) ESI TOF MassSpec with preceding 
HPLC (Agilent) run using a SUPELCOSIL™ LC-18-T reverse phase column. 
Acetonitrile was used as elution buffer. MS analyses were performed in negative 
mode, at a detector voltage of 120 V and with a pre-pulse storage of 1 µsec. 
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Results 
 
Structural overview 
Crystals of BeF3¯ -activated PleD were obtained under the same conditions as for 
PleD-act1 (13), but supplemented with GMPCPP. Data collection was performed 
with a single crystal diffracting initially to 2.5 Å. The crystal structure was solved by 
molecular replacement using the structure of PleD-act1 (PDB code: 2v0n) as search 
model (13) and was refined to 2.8 Å (Table 1). The observed electron density 
represents the whole main chain except the linker between Rec1 and Rec2 (residues 
137-148) and the C-terminal 6xHis-tag of subunit A. The structure strongly resembles 
the search model PleD-act1 sharing the same space group (Figure 1A), although both 
crystals vary by about 5 Å in unit cell axes a and b. Result of the reduced unit cell of 
PleD-act2 is a crystal contact, which leads to unfolding of the short 3’-3’’-hairpin 
in subunit B. Structural comparison of the individual domains with ones from PleD-
act1 (13) shows no further changes in the tertiary structure. Pair-wise superposition of 
the corresponding domains of PleD-act1 and PleD-act2 shows an ‘all-atom’-RMSD in 
the range of 0.5 to 1.0 Å. 
The activation of the phosphorylation sites in the Rec1 domains by the BeF3¯ •Mg2+ 
moieties results in identical modifications in both structures, PleD-act1 and PleD-
act2. In comparison to the non-activated protein (24), the modification leads to 
intramolecular repositioning of the Rec domains resulting in the formation of a tight 
(Rec1-Rec2)2 stem as was described before (13). As in PleD-act1, both GGDEF 
domains of PleD-act2 are cross-linked by two c-di-GMP dimers via the R359xxD 
motif of one domain and R313 of the other and vice versa. 
 
Active site bound c-di-GMP molecule 
The major difference between the two activated PleD structures is a different 
orientation of the c-di-GMP cross-linked GGDEF domains with respect to the (Rec1-
Rec2)2 stem. After superposition of the stems, the GGDEF domains have to be 
rotated by 8.5° with a screw component of 1.2 Å to superpose. Whereas in PleD-act1 
no direct intermolecular contacts were detected between the catalytic and the Rec 
domains, in the present structure the GGDEF domain of protomer B forms a small 
contact interface (432 Å2 –PISA (37)) with Rec1 and Rec2 of chain A (Figure 1b). 
This contact appears mainly mediated by a c-di-GMP molecule and is further 
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stabilized by a few H-bonds and a weak salt bridge (R148 (A) – D344 (B)). Indication 
that the observed intermolecular contact is not a crystallization artifact and may play 
some regulatory role in vivo, comes from previous studies on PleD (38), showing a 
four times higher activity of the R148A mutant in comparison to the wild type 
protein. The embedded c-di-GMP molecule forms rather weak contacts with the Rec 
domains (Figure 1B). One guanine base of the cyclic dinucleotide is stacked between 
R137 and P72 in van-der-Waals contact. Additionally, both bases of c-di-GMP 
enclose the hydrophobic G(144)AAA segment of the Rec1-Rec2 linker.  
Similar interaction of the c-di-GMP molecule with the catalytic site of the GGDEF 
domain via the guanine moiety has been observed before (24) (Figure 2C). Besides 
the known H-bonding to N335 and D344, in PleD-act2 the guanine’s O6-atom is in 
distance to form a polar contact with the highly conserved R366 (Figure 2B). Like in 
structure of PleD-na the 2’-hydroxyl of the ribose moiety forms a weak H-bond 
(3.1Å) with N335. Additional electron density was observed between one -
phosphate non-ester oxygen and E371’s carboxyl, which we assigned to a putative 
Mg2+-ion. Interaction between c-di-GMP and E371 via a putative Mg2+-ion further 
increases the interface between the active site and the product (Figure 2B). 
Furthermore, each of the active sites bear a crystallization condition derived sulfate 
ion at the position of the GTPS -phosphate in the structure of PleD-act1 (Figures 
2A-B), interacting with the same protein residues. In contrast to PleD-act1, no 
electron density of the catalytic Mg2+-ions A and B could be detected near the side 
chains of D327 and E370. Thus, the catalytic metal ions seem to bind to these acidic 
residues only in presence of proper substrate. To our surprise at neither of the two 
active sites any electron density could be detected for the substrate analog GMPCPP, 
although this substrate analog was present during crystallization in a two-fold excess 
compared to that of the successfully incorporated GTPS of PleD-act1 (Figure 2A). 
 
Anion binding on the stem dyad 
As in PleD-act1, a putative sulfate ion is found bound to a deep, positively charged 
pocket at the ”bottom” of the (Rec1-Rec2)2 stem on the molecular dyad axis. The 
almost buried sulfate molecule interacts with the guanidinium groups of R117 and 
R121 and their symmetry mates (Figure 3). Figure 4A shows the positively charged 
binding site formed by arginines that is surrounded by a negatively charged rim (E25, 
E245). 
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All four Rec domains of a PleD dimer are involved in the formation of this deep, 
charged cavity. Therefore, we wondered whether such a cavity is a feature of proteins 
with two consecutive Rec domains that undergo dimerization. If this is the case, 
conservation of PleD residues involved in sulfate binding should be observed. 
1070 sequences of proteins bearing two Rec domains were identified using the 
SMART web-server (39). To our surprise these sequences code only for proteins 
having either a catalytical or no output domains at all, whereas it is known that ~ 60% 
of all response regulators are DNA binding proteins (3,15) and only 11% are proteins 
with an enzymatic function (3). Of these 1070 proteins only 271 have two 
consecutive Rec domains. The two most abundant classes of these proteins are the 
DGCs with a C-terminal GGDEF domain (161 proteins) followed by ‘stand-alone’ 
Rec1-Rec2 proteins (88 proteins). 
We have analyzed the conservation profiles of residues involved in phosphorylation 
(=activation) and formation of the charged pocket in these protein classes (Table 2). 
The ‘stand-alone’ Rec1-Rec2 proteins seem to be phosphorylated not on the Rec1 but 
on their Rec2 domain. Additionally, this protein class shows no significant 
conservation of residues, which might be involved in dimerization and charge 
distribution in the cavity. 
In contrast to the ‘stand-alone’ Rec1-Rec2 proteins, Rec1-Rec2-GGDEF proteins 
seem to be activated mainly via their Rec1 domains. Although in case of PleD the 
Rec2 domain misses residues that would be involved in activation, high number of 
proteins seem to be activated at both Rec domains in the class of Rec1-Rec2-GGDEF 
proteins.  
Y26 of PleD has been shown to be essential for dimerization and to be conserved in 
proteins that are homolog to PleD (23). Due to similar and partially even higher 
conservation of residues involved in cavity formation compared to residues involved 
in dimerization (Figure 4B-C, Supplemental figure 1), the observed charged pocket in 
PleD turns out to be a characteristic of Rec1-Rec2-GGDEF proteins. 
RRs are known to interact with their cognate HKs via highly conserved hydrophobic 
residues near the phosphoacceptor site and additional polar interactions, that are HK-
RR pair specific (9). To exclude the possibility that the described charged pocket 
might be involved in RR-HK contact formation, we have compared the Rec domain 
structure of PleD with structures of Rec-HPt complexes (7,9,40,41). This analysis 
shows that residues of PleD that are homologous to the ones involved in the Rec-HPt 
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interface are distinct to the ones involved in the charged cavity formation 
(Supplemental figure 2). 
 
Stabilization of PleD dimers in presence of an anionic ligand 
The extended interaction between 5-helices of the Rec domains is substantially 
contributing to the formation of PleD dimers (Figure 3). The sulfate molecule is 
interacting with positively charged residues on one pole of the two-fold symmetric 
axis of the PleD dimer. The thermodynamic stability of the (Rec1-Rec2)2 dimer 
increases in presence of the observed sulfate molecule. As deduced from the structure 
with the help of the PISA server (39), the sulfate contributes -21 kcal/mol to the total 
G of -38 kcal/mol. 
This dimer stabilizing effect by the sulfate should manifest itself in an increased DGC 
activity, since only dimeric PleD is enzymatically active (23). Therefore enzymatic 
assays with non-activated and BeF3¯ •Mg2+ -activated PleD were performed in 
presence of sulfate and phosphate ions. To avoid product inhibition of PleD by c-di-
GMP, R148A R178A R313A mutant that shows a strongly increased Ki (13) was 
used for this experiment. In non-activated state both, sulfate and phosphate, show a 
slight inhibitory effect on the catalytic activity of PleD (Figure 5), probably by 
competing with GTP for binding to the active site as is observed for sulfate in the 
present PleD structure. In contrast, the catalytic efficiency of activated PeD is 
increased about 1.6 fold upon addition of sulfate. Phosphate on the other hand acts 
inhibiting on c-di-GMP production of PleD. The observed modulation of activity is 
thus specific to the type of the tetrahedral oxyanion and is not a mere charge-
neutralizing effect. 
 
Divalent cation dependence of the diguanylate cyclase activity 
POLs and NCs, which utilize the same structural fold as DGCs, are also known to 
show distinct enzymatic behavior in presence of divalent cations Mg2+, Mn2+, and 
Ca2+ (42-44). To observe the influence of divalent cations on the catalytic rate of 
DGCs, we performed enzymatic assays in presence of Mg2+, Mn2+, and Ca2+ ions. We 
conducted these experiments with DgcB, which is a constitutively active dimer (data 
not shown), instead of using PleD, which requires Mg2+ for dimerization in the 
activation process. DgcB requires Mg2+ or Mn2+ for catalytic activity and is inhibited 
by Ca2+-ions (Figure 6). Highest activity is detected in presence of 5 mM Mg2+ and 
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0.1-0.5 mM Mn2+, respectively. Interestingly, further increase in Mg2+- and Mn2+-ion 
concentrations leads to attenuation of the enzymatic activity. The same effect is 
observed for POLs (45-47). In case of DgcB, attenuation by manganese is 
considerably more potent than by magnesium. 
In case of POLs usage of manganese instead of magnesium results in lower 
enzymatic fidelity and was discussed to be due to loose coordination requirements of 
manganese (43,48). Regardless the nature of used divalent cations, Mg2+ or Mn2+, 
analysis of catalytic products of PleD and DgcB by ESI-TOF MS resulted in a single 
species with a mass of 690.1 g/mol that is in agreement with the mass of c-di-GMP. 
No product intermediates, such as pppGpG, have been detected, arguing for high 
prevalence of precise, quasi simultaneous formation of both phosphodiester bonds 
once the substrate-enzyme complex has formed. 
II.2  Second crystal structure of activated PleD – new insights in the mechanisms regulating dimerization and catalysis 
 - 42 - 
Discussion 
 
Function of the Rec2 domain in the Rec1-Rec2-GGDEF proteins 
The crystal structures of the atypical RR and DGC PleD (13,24) have shown the 
pivotal role of the Rec1 domain in the phosphorylation dependent activation process. 
The Rec2 domain, on the other hand, was assigned an adaptor role, due to absence of 
residues that are involved in the phosphorylation process. Therefore, one of the main 
questions concerning structural architecture of DGCs with PleD-like Rec1-Rec2-
GGDEF domain composition is, what function is fulfilled by the second Rec domain 
in these proteins? 
Although some of these proteins may utilize tighter control of enzymatic activity 
using two phosphorylatable Rec domains, a single Rec domain is sufficient for 
dimerization and therefore for DGC activity, as it was shown for WspR, a Rec-
GGDEF domain protein (49,50). In case of PleD, residues of the Rec2 domain, which 
would be involved in activation by phosphorylation are missing (Table 2), rendering 
the domain non-functional. Ability of this Rec2 domain to interact with HKs is also 
lost due to the replacement of strongly conserved hydrophobic residues that are 
needed for interaction with HKs (9) by charged residues (R164 and R168 in 1-helix, 
as well as D233 in the 4-4 loop). Therefore the non-functional Rec2 domain cannot 
be involved in the regulatory mechanism of signal desensitization by capturing HKs 
and in turn prevent the transfer of the phosphoryl group to the phophorylatable Rec1 
of PleD. Additionally, involvement of Rec2 residues, R148 and R178, in the allosteric 
control of the DGC PleD, cross-linking Rec2 and GGDEF domains via a c-di-GMP 
dimer (24), must be an unique feature of PleD, due to a complete lack of conservation 
of these residues in homolog proteins (38). 
We have found an evidence for the structural relevance of the Rec2 domain in the 
class of Rec1-Rec2-GGDEF domain proteins. Both Rec domains are involved in 
formation of a charged cavity in the activated PleD dimer. This cavity is spatially 
distinct from the HK recognition area (Supplemental figure 2). Therefore, the found 
charged pocket, which would be not formed in absence of Rec2, might represent a 
binding site. 
 
Induction of a ligand binding site by dimerization                                                     . 
Several aspects support the idea of an anionic binding site formed by the dimer 
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interface of the Rec1-Rec2-GGDEF domain proteins. The cavity depends structurally 
on protein dimerization. Therefore residues involved in dimerization and cavity 
formation must be similarly conserved. This is the case in PleD. The high 
conservation of R121 depicts the importance of this residue in the maintaining the 
cavity architecture as well as in the recognition of a negatively charged ligand. 
Another aspect is the stabilization of the protein dimer in presence of a putative 
ligand, which would neutralize the positively charged area, formed by all four 
arginines (R117, R117’, R121 and R121’) (Figure 3). RRs coexist in solution in 
inactive and active conformations and phosphorylation shifts this equilibrium 
predominantly to the active conformation (51,52), which in case of PleD leads to 
dimer formation. In presence of the putative ligand, the equilibrium most probably 
shifts to the active conformation, stabilizing the dimer and thus enhancing the c-di-
GMP production (Figure 5). The putative ligand could also play a role in the lifetime 
enhancement of the phosphorylated protein species. The intrinsic lifetime of 
phosphorylated RRs is in range of seconds to hours (53), but it was shown to be 
profoundly prolonged by interaction with other proteins (6). 
 
Nature of the putative ligand 
The presence of a specific cavity in dimeric Rec1-Rec2-GGDEF proteins raises the 
fundamental question about the nature of the putative ligand. The surprising result of 
the enzymatic assay that BeF3¯ -activated PleD can be further activated by sulfate, but 
is inhibited by phosphate, opened the possibility of sulfate being the specific activator 
of PleD. But analysis of X-ray structures with bound tetrahedral oxyanions has shown 
crystallization condition derived sulfate ions mainly bound to protein surfaces 
forming one or maximally two contacts (54). The residues, which interact with these 
sulfate ions, are very often not conserved, due to a comparably negligible relevance 
of sulfate in-vivo. One of such sulfate ions is also found in the PleD-act1 structure 
(13) near the non-functional phosphorylation site of Rec2 (Figure 4A). The interface 
of the sulfate ion localized at the two-fold symmetry axis of the (Rec1-Rec2)2 dimer 
in both structures of activated PleD is more specific. Such a positively charged 
binding pocket, which almost engulfs the anion and forms extended contacts to the 
ion, is typical for phosphate and phosphate containing ligands (54-56). 
Some considerations deprive sulfate of the role of the seeked ligand. (I) 
Inappropriately for an activator, sulfate acts as an competitive inhibitor binding to the 
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active site (Figure 2B). (II) The sequence alignment of Rec1-Rec2-GGDEF proteins 
shows not only conservation of the binding site’s R117 and R121, but also of residues 
in the rim of the cleft (E25, E245), which do not interact with the sulfate ion at all. 
Therefore, the putative ligand is most probably an organic molecule bearing a 
tetrahedral oxyanion group or a specific phospholipid or it could be a phosphorylated 
protein, which shows some degree of symmetry in line with the symmetric 
architecture of the cleft. 
 
Possible mechanism of PleD sequestration to the stalked pole in C. crescentus 
As stated before, PleD is involved in polar differentiation of the asymmetrically 
dividing bacterium C. crescentus (16). Sequestration of PleD to the stalked pole upon 
phosphorylation has been shown to be independent of DGC activity (23). 
Furthermore, it appears that phosphorylation induced dimerization is the prerequisite 
to drive PleD to the pole (23). 
Therefore the interface that directs PleD to the pole has to satisfy several 
requirements. (I) It must be encoded by both protomers of a PleD dimer. (II) 
Sequestration to the pole is most probably mediated by Rec domains and not by 
catalytic GGDEF domains, since the later ones have to be able to form a catalytically 
competent and flexible dimeric subunit (24). (III) The residues that are involved in 
this interface have to show some degree of conservation and specificity. 
Most interestingly, all these requirements are perfectly fulfilled by the charged, two-
fold symmetric cleft in the dimer interface. Further in-vivo studies are needed to 
demonstrate the importance of the described cleft in the sequestration process of 
activated PleD as well as to identify the cognate interaction partner of PleD at the 
stalked pole. 
 
Utilization of ‘two-metal assisted catalysis’ by DGCs 
Although the crystal structures of PleD (13,24) led to remarkable insights into the 
enzymatic process utilized by DGCs, which leads to production of one molecule c-di-
GMP and two molecules pyrophosphate by condensation of two GTP molecules, 
several questions stayed unanswered. Some of them concern the catalytic mechanism 
itself. The shared structural fold of GGDEF domains, ACs and POLs as well as the 
presence of two putative magnesium ions in the active site of PleD-act1 indicate 
utilization of the ‘two-metal assisted catalysis’ mechanism by DGCs. 
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The main feature of the ‘two-metal assisted catalysis’ is the presence of two 
appropriately coordinated Mg2+ -ions. In our recent PleD-act1 structure electron 
density for both catalytic Mg2+-ions was detected (13). Unlike the accurate electron 
density representing the position of metal ion B, the electron density cloud that 
represents metal ion A, is rather diffuse (13) (Figure 2b). This is reminiscent of the 
situation for NCs (57,58) and POLs (44,59) that also show alternative positions for 
metal ion A, with an A to B ion-distance varying from 3.5 to 4.5 Å (32,60). It was 
proposed that the 3’OH-hydroxyl, which is coordinated by Mg2+-ion A, assumes the 
proper attacking position at an interatomic distance of 3.5 Å between both Mg2+-ions 
(44,60). Longer distances will keep the 3’OH-group out of range for the nucleophilic 
attack, rendering the enzyme in its ‘resting’ state. 
This theory is supported by biochemical data showing inhibition by Ca2+ (42,61-63) 
and enhanced activity in presence of Mn2+ (42,43,64). Ca2+-cations show in POLs 
similar coordination geometry as Mg2+-ions (65), but have a larger intermetal distance 
of 3.9 Å in comparison to Mg2+-ions (3.2 Å) (66). Mn2+-ions, on the other hand, have 
an interatomic distance of 2.9 Å (66) and they do not obey to the strict octahedral 
coordination behavior of Mg2+-ions. 
This catalysis relevant metal ion variability in position may apply for DGCs as well. 
Similar to POLs, DgcB as a representative of DGCs needs magnesium or manganese 
for catalysis, but is inhibited by calcium (Figure 6). Both, the structure of PleD in 
complex with two putative magnesium ions (Figure 2A), and the catalytic behavior of 
DgcB in presence of divalent cations, corroborate this theory. 
Additionally, the DGCs and POLs seem to share the cation induced attenuation 
behavior (45-47). In both cases high divalent cation concentrations lead to inhibition. 
Although this behavior is still not completely understood, reduced product release 
rates in presence of high divalent cation concentrations was proposed as a possible 
mechanism (44). Mutational studies in RNase H indicate involvement of a glutamate 
(E188) in the attenuation process (47). Substitution of this residue in E.coli DNA Pol 
I’s Klenow fragment to aspartate and alanine results in 30 and 70% activity loss, 
respectively (45), but in unaffected substrate binding (67). This residue (E188) was 
structurally shown to move in and out of the active site of RNase H, interacting with 
metal ion A (46). It was suggested to contribute actively to the release of the product, 
due to its high mobility. Interestingly, E371 of PleD’s GGDEF motif, which contacts 
the phosphate group of the c-di-GMP molecule via a Mg2+-ion (Figure 2B), takes an 
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analogous position in the structure as E188 in RNase H. In PleD the conservative 
mutation E371Q results in complete loss of the enzymatic activity (38), showing the 
exclusivity of this residue for DGCs. These structural and biochemical observations 
suggest involvement of E371 in the process of product release. 
 
Conformational change of the active site as prerequisite for catalysis 
The recent structure of PleD-act1 in complex with two putative magnesium ions and 
the the substrate analog GTPS (13) gave many insights in the mechanism of 
substrate binding by DGCs. A reasonable catalytic mechanism of ‘two-metal assisted 
catalysis’ was proposed that is also used by NCs and POLs.  
For POLs it has been shown that for the activation of the 3’-OH group, both metal 
ions have to be in coordination distance with the non-bonding RP-oxygen in a 
symmetrical manner (31,60,68). When this requirement is not fulfilled, the attacking 
hydroxide group is not in-line for the substitution reaction or it is too far away for 
being activated by metal ion A. Therefore the binding mode of the substrate analog 
GTPS in the PleD-act1 structure (13) doesn’t represent a protein-substrate complex 
that is ready for the catalytic reaction. The atom in the RP position, which is a sulfur, 
is not in coordination distance to metal ion A and B, possibly due to the larger atomic 
radius of sulfur in comparison to oxygen and the single bond character of the S-P 
bond (69,70). Similar orientation of RP-S nucleotides was observed before in the 
structures of RNase H (71), tmAC (58) and sAC CyaC (72). In our recent publication 
(13) we demonstrated that the GTPS P can be brought in contact with metal ion A 
without disturbing any protein-ligand interactions. Nevertheless, it is impossible to 
bring the non-bridging RP-oxygen in catalysis relevant coordination between both 
metal ions by rotation without breaking protein-nucleotide interactions, either to the 
P or the guanine moiety. 
In the T7 RNAP structure (59) the active site bound substrate analog AMPCPP is 
trapped in the productive state, ready for the in-line attack. It is possible to fit the 
C5’PCPP moiety of this molecule into the active site of PleD (Figure 2D), keeping in 
mind the following restrains. (I) The position of the P moiety has to be retained, 
due to the extended contacts of these phosphates with the P-loop (13). (II) The P 
RP-oxygen has to replace the imperfect sixth coordination of E370’s second carboxyl 
group to Mg2+-ion B, taking the apical position of the octahedral Mg2+-coordination 
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opposite to the main-chain carbonyl 328. (III) The P RP-oxygen must be 
symmetrically coordinated by both metal ions as postulated for the productive state 
(31). As a result, the C5’ position of the fitted C5’PCPP and the GTPS moieties 
would deviate substantially (2.7 Å, Figure 2D). This implements not only a new 
conformation for the substrate, but also for the active site in the catalysis relevant 
GGDEF domain dimer. 
In comparison to the extensive coordination of - and -phosphate moieties and the 
predefined positions of both Mg2+-ions by the coordinating residues D327 and E370 
(Figure 2A), the interaction of the ribose and the guanine moieties with the protein is 
less elaborated. The main contact is established via N335 and D344, which are part of 
the helices 1 and 2. 
In NCs, homolog helices show large flexibility and they are involved in dimerization 
(32,57,73), in the mechanism of induced fit of the active site (72,74,75), and in the 
activation process by interaction with the GS subunit of G-proteins (58,76). 
Similarly, in POLs the spatially corresponding “O”-helix is responsible for the 
transition between an “open” and a “closed” (=catalytically relevant) conformations 
of the active site (59,77). These conformational rearrangements in the active sites of 
NCs and POLs observed in the substrate analog bound state led to postulation of a 
substrate induced “active site closure”-mechanism (57-59). Structural comparison of 
non-ligated GGDEF domain structures, WspR (50) and NP_951600.1, with the 
ligated structure of PleD-act1, shows minor delocalization (1-2 Å) of helices 1 and 
2 with respect to the well superposing -sheet core as a rigid body (Supplemental 
figure 3). Interestingly, the alternative position of 2 doesn’t induce changes in 
positions of the catalytically relevant residues. Side chains of N335 and D344 occupy 
almost identical positions in all three structures. Therefore, it seems that substrate 
binding doesn’t induce conformational changes in the active site of the GGDEF 
domains.  
An alternative mechanism of “active site closure”, which is driven by catalysis, was 
proposed for NCs (74,75). It is inspired by the fact that some structures of substrate 
analog bound ACs show an “open” conformation while some ligand-free structures in 
complex with activators exhibit a “closed” one (58). 
How probable is utilization of a similar mechanism by the GGDEF domain proteins, 
which form a single, dimeric active site to be catalytically competent? Several facts 
suggest dimerization induced conformational changes in the active site. (I) Although 
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the GGDEF domains possess all necessary residues for the intramolecular cyclization 
reaction (the reaction that is performed by NCs), there are no reports of a DGC 
producing cGMP as side product. (II) The substrate analog GTPS bound to the 
active site of PleD (13) cannot adopt the productive state conformation without 
loosing its coordinating interactions to the protein. (III) The 1/2 helices of the 
GGDEF domain, which similarly to the NCs are most probably involved in 
dimerization of the catalytic domains, exhibit some degree of flexibility. Moreover 
conformational changes in this region would result in an alternate position for the 
guanine moiety of the substrate.  
 
Modeling of a processive substrate-GGDEF domain complex 
Although Diadenylate Cyclases (DACs) (78) and DGCs do not share any structural 
similarities the products of both enzymes, c-di-AMP (79) and c-di-GMP, differ only 
in the kind of the nucleobase. Both products utilize the “U”-shape conformation, 
where the parallel nucleobases are perpendicularly arranged to the ribosyl-phosphate 
macrocycle. DisA was crystallized in presence of both, its product c-di-AMP and the 
substrate analog 3’-deoxy-ATP bound to the active site, respectively (78). Perfect 
superposition between the 2-fold symmetrically arranged substrate analog molecules 
and the product, c-di-AMP, are observed. This means that the conformation of c-di-
AMP is pre-coded by the orientation of both substrate molecules with respect to each 
other and that c-di-AMP experiences no structural changes post-catalytically.  
The catalytic mechanism of DACs is distinct from the ‘two-metal ion assisted’ 
catalysis due to the absence of the putative metal ions as well as the putative residues 
coordinating them. Therefore, it is clear that proper geometry of the substrates 
required for the nucleophilic in-line attack in DGCs will differ from the one in DACs. 
Nevertheless the global, pre-catalytic conformation and the intramolecular orientation 
of both substrate molecules in DGCs and DACs must be very similar to generate 
products with identical conformation. 
We have fitted both 3’deoxy-ATP molecules as a single rigid body in the active site 
of PleD. Since the triphosphate moieties of these ligands don’t show the predicted 
ideal conformation for the “two-metal assisted catalysis” (Figure 2D), restrains had to 
be imposed in symmetrical manner for both nucleotides. The phosphates-moiety of 
the “cis” nucleotide (nucleotide that forms direct contacts with the GGDEF domain) 
was aligned in coordination range to metal ion B. Additionally, the -phosphate’s 
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non-bridging oxygen atoms were restrained to coordinate both metal ions 
symmetrically. The imaginary 3’OH-group (missing in this substrate analog) of the 
“trans” nucleotide was aligned to be in coordination distance to metal ion A, which 
activates this group for the nucleophilic attack. 
Our model doesn’t show any prominent clashes between the nucleotides and the 
protein, but two prominent features (Figure 2E). The first feature is the distinct 
position of the nucleoside moiety in the model and the PleD-act1 structure. Atom O6 
of the nucleobase comes hereby in contact distance with the highly conserved R366, 
as is observed for the c-di-GMP molecule in the PleD-act2 structure. Additionally, the 
C5’ atoms of the fitted C5’PCPP and the 3’deoxy-ATP moieties take an almost 
identical position (Figure 2D-E). Thus, the substrate/Mg2+-ions loaded half-active 
sites undergo quite likely a conformational change upon dimerization of the GGDEF 
domains to allow proper substrate alignment for the activation of the 3’OH-hydroxyls 
and the subsequent in-line attack. As stated before the rather flexible helices 1 and 
2 are most probably involved in this process. 
The second feature of this model is the position of the ribose in “trans”. Its 2’OH 
group is localized in H-bond distance to the carboxyl group of E371 in “cis” (Figure 
2E), which is simultaneously close to metal ion A (~3.3 Å) (Figure 2A). For the in-
line attack to occur, the “trans” 3’OH-hydroxyl has to be properly aligned with 
respect to the metal ion A and P in “cis”, and vice versa. Actually, no other residues 
than E371 are in proximity to fulfill this task. 
Taking into account that for the production of a c-di-GMP molecule two nucleophilic 
attacks have to be performed simultaneously to avoid production of unwanted 
intermediates and site-products, E371’s possible ‘guiding role’ appears even more 
attractive. Alignment of the 3’OH-hydroxyls for the in-line attack via the “cis”-
“trans” cross-interaction of both E371 with both 2’OH- and not 3’OH-groups, would 
allow only simultaneous nucleophilic attacks. Misalignment of one of the attacking 
groups would hereby result in inappropriate distances between each of the “trans” 
3’OH-“cis” P groups and in inappropriate angles for the in-line attack (Figure 8A). 
 
Modeling of an active site forming GGDEF domain dimer 
Fitting of both substrate analogs in the active site of PleD’s GGDEF domain allowed 
us to generate the missing two-fold symmetry related GGDEF domain (Figure 7). 
Lack of serious clashes in the model of the GGDEF domain dimer affirms our rigid 
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body fitting of the substrate analogs to the substrate binding site (Figure 2E). As 
expected for an activated PleD dimer forming the (Rec1-Rec2)2 stem, the model 
shows a distance of less than 6 Å between the N-termini of both GGDEF domains. 
Additionally, the N-terminal 0-0’-hairpins, being conserved only in DGCs (32), are 
arranged as a single -strand. As it was proposed before, helices 1 and 2 are 
involved in dimer contact formation and it is tempting to envisage that closure of 
these helices around the active site will lead to contact formations with the highly 
conserved residues of the helix 4. 
 
Hypothetical reaction scheme for DGCs 
Our biochemical, structural, computational and comparative investigations in the 
activity of PleD let us propose a putative catalytic mechanism for PleD. The catalytic 
reaction starts with dimerization of the GTP/Mg2+ bound GGDEF domains, which is 
induced upon phosphorylation dependent dimerization of the (Rec1-Rec2)2 stem. 
Dimerization of the GGDEF domains induces conformational changes in helices 1 
and 2 with respect to the core -sheet, resulting in rearrangements in the substrate 
binding site. This and the bridging of E371 between metal A and the 2’OH-group of 
the “trans”-substrate lead to a proper alignment of both 3’OH-groups for the 
nucleophilic in-line attack on the -phosphorus atoms (Figure 8A). The occurring of 
the “double”-reaction action is probably quasi simultaneous. 
As suggested earlier (13,24), the subsequently formed pentacovalent phosphate 
intermediate (Figure 8B) could be stabilized by K332, compensating for its negative 
charge. Most recently it was shown that positively charged residues (mainly lysines) 
in the “O”-helix of POLs are actively involved in the mechanism of pentacovalent 
phosphate intermediate protonation as general acids (80). Hereby, the chemical 
reaction of protonation turns out to be the rate limiting step for nucleotide 
incorporation by polymerases. The same role may be attributed to K332 in PleD. In 
the case of protonation reaction being equally the rate-limiting step in DGCs, 
formation of both pentacovalent intermediates would occur faster than the protonation 
reaction. This would additionally enhance the enzymatic precision of DGCs. 
The protonation reaction leads to a breakdown of the intermediate into c-di-GMP and 
two pyrophosphate molecules. In this state the joint coordination of both metal ions 
by the cleaved phosphate is not feasible any longer due to charge repulsion between 
the products (Figure 8C). In DGCs charge repulsion between the products will most 
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probably force the dimeric active site to open up. Similarly to NCs (32,81) and POLs 
(43,59,60), it is believed that c-di-GMP will leave the active site first due to a 
stronger interaction of the pyrophosphate molecules with the active site. In POLs 
release of the -phosphate bearing product is concomitant with release of metal ion A 
(43,59,60). The E371-Mg2+-ion-phosphate bonding in PleD-act2 may represent such a 
state in PleD (Figure 2C). Further movement of c-di-GMP out of the active site, alike 
the observed situation in the structure of PleD-na (24), would lead to the release of 
the metal ion (Figure 8C). 
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Figure legends 
 
Figure 1. Ribbon diagram of activated PleD dimer in complex with c-di-GMP 
The domains Rec1, Rec2 and GGDEF are colored red, yellow and green, 
respectively. The GGDEF signature motif is highlighted in blue. Ligands and 
interacting residues are shown in full. (A) The main difference in both structures of 
activated PleD - rigid body repositioning of cross-linked GGDEF domains with 
respect to the stem is represented by the hinge as straight black line. Bound sulfate 
molecules are detected at both active sites, as well as in the two-fold symmetric 
(Rec1-Rec2)2 dimer interface. Phosphate mimicking BeF3¯ •Mg2+ ligands are 
localized at both phosphorylation sites. Intercalated c-di-GMP dimers are found 
cross-linking the GGDEF domains, binding to both allosteric sites (13). A single c-di-
GMP molecule interacts with the GGDEF active site and Rec domains of second 
protomer (B). 
 
Figure 2. Substrate analog and product binding to the active site of PleD 
The ribbon representation shows the protein in green and the GGDEF signature motif 
in dark blue. Ligands, interacting residues as well as the P loop main chain (328-331) 
are shown in full. (A) Substrate analog GTPS and two putative magnesium ions 
(labeled A and B) bound to PleD-act1 (PDB code 2v0n). (B) Product c-di-GMP and a 
putative Mg2+ ion bound to PleD-act2. (C) C-di-GMP bound to PleD-na (PDB code 
1w25). (D) C5’PCPP moiety of a AMPCPP molecule from the T7 RNAP structure 
(PDB code 1s76) is fitted in the active site of PleD-act1 and restrained with respect to 
the positions of both Mg2+ ions (see main text). (E) Both 3’deoxy-ATP molecules 
from the DisA structure (PDB code 3c23) are fitted as a rigid body in the active site 
of PleD-act1 and restrained (see main text). For clarity GTPS is drawn in thinner 
lines. 
 
Figure 3. Sulfate binding on the molecular dyad of the (Rec1-Rec2)2 stem 
Secondary structure elements, which are involved in dimerization and sulfate binding 
in the (Rec1-Rec2)2 dyad interface, are shown as ribbon. Residues involved in sulfate 
binding and formation of the symmetric charged cleft are shown in full. Green surface 
around dyad-related L124 and V125 represents the hydrophobic contact between 5-
helices (Rec1).  
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Figure 4. Conservation and charge distribution along dimer interface of the stem 
The GGDEF domains are not shown for clarity. (A-B) View onto the (Rec1-Rec2)2 
stem along its two-fold symmetry axis, from the bottom of the view in figure 1 and 2. 
(A) Surface charge distribution, generated by APBS tools (82), in the stem of PleD-
act1 (PDB code: 2v0n) shows BeF3¯ •Mg2+ binding to the acidic pocket of the 
phosphorylation sites, a sulfate deeply buried at positively charged dimer interface 
and a sulfate binding to an exposed, basic patch in Rec2’.  
Mapping of residue conservation score; using the ConSurf web-server (83), onto the 
dimeric stem (B) and its dimer forming face (C) of PleD-act2 according conservation 
of residues in Rec1-Rec2-GGDEF proteins (magenta = strong, white = medium, blue 
= not conserved). 
 
Figure 5. Characterization of PleD DGC activity in presence of tetrahedral oxyanions, 
sulfate and phosphate 
The product quantity was normalized taking the c-di-GMP amount produced by 
BeF3¯ •Mg2+ activated PleD R148A R178A R313A as reference. For details see 
Materials&Methods. 
 
Figure 6. Characterization of DgcB DGC activity in presence of divalent cations 
Catalytic activity varying the concentrations of magnesium (full circles) and 
manganese (open triangles) and calcium (+ 2 mM Mg2+) (full rectangles) is present. 
The product quantity was normalized according the c-di-GMP amount produced by 
DgcB in presence of 5 mM Mg2+. 
 
Figure 7. Superposition of GGDEF domains on fitted 3’deoxy-ATP molecules 
The GGDEF domains are represented as ribbon (A) and surface (B) and are colored 
according their residue conservation (magenta = strong, white = medium, blue = not 
conserved). Secondary structure elements that are involved in dimerization are 
labeled. The GGDEF domains were superposed on the fitted substrate analogs (see 
main text), which together with catalytic metal ions are shown in full.  
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Figure 8. Schematic representation of the catalytic cycle of DGCs 
(A) Prior to catalysis GTP and magnesium ions bind to the DGC active sites. Besides 
minor coordination of the nucleotides by its base (see main text), the ligand is 
interacting mainly via the triphosphate moiety with main chain amides of the P loop 
and the catalytic metal ions A and B. Metal ion B is octahedrally coordinated by the 
α-, - and -phosphates of the nucleotide, the carboyl groups of D327 and E370 as 
well as main chain carbonyl 328. The role of Mg2+ (B) is proper positioning of the 
triphosphate moiety for the reaction and neutralization of charge during catalysis. The 
second Mg2+ (metal ion A), which is coordinated by -phosphate and carboyl groups 
of D327 and E370, initiates the reaction by lowering the pKa values of the 3’-
hydroxyl groups. The proton acceptor is not known, but it is probably a water 
molecule. For the enzymatic reaction to happen, both nucleotides of both active sites 
have to be properly aligned. First, the non-bridging oxygen of P has to form 
symmetrical contacts to both metal ions, to bring the attacking group in contact range 
of metal ion A. Secondly, the attacking 3’OH-group must be in-line with the scissile 
P-O bond. Upon encounter of both substrate loaded active sites the ribosyl 2’OH-
group probably interacts with E371 of the other GGDEF domain, aligning the 
attacking group for the in-line reaction. Proper positioning of the attacking ribosyl via 
2’OH would result in high product precision of DGCs. Only when both E371-2’OH 
contacts are formed, then the attacking groups have the proper distance and are in-line 
for the nucleophilic attacks, which then happen simultaneously. (B) We propose that 
the charge of the pentacoordinated intermediate is stabilized by K332, which 
subsequently protonates the leaving pyrophosphate group. (C) Product release may be 
initiated by opening of the GGDEF domain dimers, followed by E371-metal ion A 
guided dissociation of the c-di-GMP molecule. 
 
Figure S1. Conservation score of R117 and R121 
Conservation score of R117 and R121 in Rec1-Rec2-GGDEF proteins generated by 
the web based application WEBLOGO (84). 
 
Figure S2. Surface mapping of residues contributing to the Rec-HK interaction 
Residues of PleD, which could be involved in interaction with its cognate histidine 
kinases, are mapped black on the surface of the stem (same view as in figure 3 and 
color code as in figure 1). These residues correspond to homologous residues of RR 
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Spo0F, which are involved in interaction with HPt of Spo0B (40). Mapping was 
performed on all four Rec domains, since many Rec1-Rec2-GGDEF domain proteins 
utilize phosphorylation of both Rec domains (see main text). Rec domains contribute 
mainly via 1-helix and the phosphorylation site surrounding -loops to the HK-Rec 
interface. 
 
Figure S3. Superposition of GGDEF domains of PleD, WspR and NP_951600.1 
The GGDEF domains of PleD, WspR and NP_951600.1 (PDB codes: 2v0n, 3bre and 
3ezu) were aligned superposing Cα-atoms of the central β-sheet and are shown as 
ribbon in green, black and magenta, respectively. N335, D344, E370 and E371 of 
PleD and homologous residues of WspR and NP_951600.1 are shown in full. For 
better understanding ligands of PleD – the GTPαS molecule and the two putative 
magnesium ions are included.  
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 PleD (2WB4.PDB) 
Data collection 
 
Space group P21212 
Cell dimensions:  
    a, b, c (Å) 123.56, 127.43, 88.13 
    α, β, γ (°) 90, 90, 90 
Resolution (Å) 70.0 - 2.5 (2.64 – 2.5)* 
Rmerge 10.2 (28.5) 
I/σI 12.9 (5.3) 
Completeness (%) 87.0 (62.4), [95.1 (81.6)]** 
Redundancy 3.4 (3.3) 
  
Refinement 
 
Resolution (Å) 2.8 
No. reflections 31415 
Rwork/ Rfree 24.0 / 26.8 
No. Atoms  
    Protein 6908 
    Ligand/ion 256 
    Water 50 
B-factors (Å2)  
    Protein 17.5 
    Ligand/ion 12.2 
    Water 6.37 
R.m.s. deviations  
    Bond lengths (Å) 0.015 
    Bond angles (°) 1.6 
* Highest resolution shell is shown in parentheses. 
** Second pair of values represents completeness to a resolution of 2.8Å 
 
Table 1: Data collection and refinement statistics 
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Table 2: Conservation of Rec domain residues in PleD homolog proteins 
Residue function PleD residues 
stand-alone    
Rec1-Rec2 
proteins 
Rec1-Rec2-
GGDEF proteins 
phosphoacceptor 
(Rec1) 
D53 25% (D) 93% (D) 
T83  73% (T/S) 95% (T/S) 
“Y-T”-coupling 
(Rec1) F102 26% (F/Y) 95% (F/Y) 
phosphoacceptor 
(Rec2) 
N202 94% (D) 72% (D) 
V232 88% (S/T) 65% (S/T) 
“Y-T”-coupling 
(Rec2) I251 31% (F/Y) 89% (F/Y) 
dimerization Y26 np 34% (Y) 
R117 27% (RK) 47% (RK) 
R121 5% (R) 63% (R) 
E25 25% (E) 32% (E) 
charged cavity 
formation in the 
(Rec1/Rec2)2 stem 
interface 
E245 5% (E/D); 9% (K) 31% (E/D); 39% (K) 
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Abstract 
The diguanylate cyclase PleD, which produces the bacterial second messenger c-di-
GMP by a productive GGDEF domain dimer, is known to be tightly regulated. One of 
the regulatory mechanisms is the phosphorylation dependent dimerization of PleD via 
its N-terminal response regulator domains. Furthermore, PleD’s activity is controlled 
by inhibition, binding allosterically its product c-di-GMP. 
Enzymatic and biophysical techniques (SPR, AUC and CD) were used to shed light 
on details of the allosteric product inhibition on the molecular level. Our SPR 
experiments confirm binding of c-di-GMP to the allosteric site in the dimeric form. 
The binding itself depends strongly on the intact primary inhibition site (IP-site: RxxD 
motif and R390) and to a lesser amount on the secondary I-sites (IS,DGC: R313; IS,D2: 
R148, R178). Importance of the IS-sites in the c-di-GMP dependent domain-cross-
linking was shown by thermal unfolding of PleD. Additionaly, in combination with 
previously published results our new I-site mutants show unambiguously that binding 
of c-di-GMP to the IP alone is insufficient for the inhibition. Therefore, all these
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experiments clearly prove the previously proposed “inhibition by domain 
immobilization” mechanism. 
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Introduction 
 
The dawning of the bis-(3’-5’)-cyclic dimeric guanosine monophosphate (c-di-GMP) 
as a global second messenger in bacteria was postponed for almost twenty years since 
the day of its discovery (1). The ubiquitous bacterial second messenger is nowadays 
known to be involved in processes like cell cycle progression (2), cell differentiation 
(3), multicellular behavior (4) as well as interaction between bacteria and their 
eukaryotic hosts (5,6). The main task of c-di-GMP, hereby, seems to be switching the 
bacterial faith between two lifestyles: the sessile, environment-persistent, surface-
attached one on the one hand and the motile, often virulent one on the other. The 
inverse regulation of biofilm formation and virulence was shown by knock-outs of the 
c-di-GMP degrading phophodiesterase VieA in Vibrio cholerae (7,8). 
Although c-di-GMP takes part in such a high variety of cellular processes, the 
downstream targets of the second messenger are only starting to emerge, e.g. the 
PiLZ domain proteins (9) or riboswitches (10). The identification of the proteins 
involved in biosynthesis and breakdown of c-di-GMP turned out to be less 
problematic. This task is performed by diguanylate cyclases (DGCs) and 
phosphodiesterases (PDEs) containing enzymatically active GGDEF and EAL/HD-
GYP domains, respectively. The domains are named after the conserved consensus 
sequences in their active sites. The interesting aspect, hereby, is the high number of 
these proteins in the genomes of single bacterial species, peaking in the genome of 
Vibrio vulnificus coding for nearly 100 GGDEF and EAL domain proteins. 
In order to produce a c-di-GMP molecule the DGCs consume two molecules of GTP. 
The PleD from C. crescentus (11) represents one of the best studied DGCs. The 
PleD’s DGC activity is strongly regulated by two distinct mechanisms – the N-
terminal, regulatory domain mediated dimerization and the allosteric product 
inhibition by c-di-GMP (12-14). 
Crystal structures of PleD (12,14) have shown binding-capacity for only one GTP 
molecule per a GGDEF domain. Subsequent experiments have shown the necessity of 
the dimeric form for DGCs to be able to produce c-di-GMP (15). Since the GGDEF 
domains are unable to dimerize on their own (P. Wassmann unpublished data), the 
DGCs use additional N-terminal domains for this task. Often, these dimerization 
domains exhibit regulatory functions. The GGDEF domain proteins are frequently 
found in combination with GAF, PAS, Rec and other regulatory domains. PleD 
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consists besides the C-terminal GGDEF domain of one phosphorylatable and one 
degenerate response regulator domain (Rec1 and Rec2). Upon phosphorylation by its 
cognate His-kinases PleC and DivJ (16) PleD dimerizes via its Rec domains forming 
a (Rec1-Rec2)2 stem (14). In the activated state the flexible GGDEF domains form a 
joint active site that is able to produce c-di-GMP. 
Inhibition of PleD by allosterically binding c-di-GMP represents another regulatory 
mechanism. The crystal structures of PleD (12,14) have shown a c-di-GMP dimer 
bound to an allosteric site of the GGDEF domain (primary inhibition site = IP). In 
case of PleD the IP consists of the RxxD motif and arginine 390. Moreover, the c-di-
GMP dimer cross-links the GGDEF domain either with the Rec2 domain of the same 
protomer or with the GGDEF domain of the second protomer in a PleD dimer ((14)– 
Figure 7). Both arginines, R148 and R178, of the Rec2 domain interacting with c-di-
GMP are called the secondary inhibition site IS,D2. And arginine, R313, in the 
GGDEF domain, which is involved in the cross-link mechanism, is analogously 
called IS,DGC. Due to a high conservation score of the RxxD motif, its presence in the 
sequences of DGCs was proposed to be an indicator for c-di-GMP dependent 
regulation in these DGCs (13). 
Combining biochemical and biophysical approaches studying PleD, we sought a 
closer view on these regulatory mechanisms. We were particularly interested in the 
following questions. Is the sole presence of the RxxD motif sufficient to bind and to 
inhibit DGCs, e.g. PleD? What are the details of the allosteric binding process of c-di-
GMP to PleD concerning the binding stoichiometry as well as the order of the binding 
events? And which functions do the secondary inhibition sites (IS-sites) as well as 
R390 have in the c-di-GMP dependent inhibition process, exactly? 
II.3 Biochemical and biophysical analysis of c-di-GMP dependent inhibition of the diguanylate cyclase PleD 
 - 72 - 
Materials and Methods 
 
PleD cloning 
A QuickChangeII Site-Directed Mutagenesis Kit (Stratagene) was used to create PleD 
mutations, R390S and R148A R178A R313A R390S (= IS,all/R390 mutant), taking as 
templates pRUN plasmids (derived from the pBR322 vector) containing the C-
terminally His6-tagged wild-type gene (12) or the R148A R178A R313A triple 
mutant(= IS,all mutant) (14). The wild-type PleD and mutants were expressed and 
purified as described elsewhere (14). 
 
Enzymatic assays 
The DGC activity of wild-type and mutant PleD at a nominal concentration of 20 µM 
in presence of c-di-GMP was analyzed by detection of the site-product pyrophosphate 
using a pyrophosphatase-coupled spectrophotometric assay. The details of the assay 
were reported before (12). The PleD samples were incubated with c-di-GMP for at 
least thirty minutes prior to the start of the enzymatic reaction adding 100 µM GTP. 
To obtain the IC50, the specific activity of PleD mutant R390S as a function of [c-di-
GMP] were fitted by a single exponential with the program SigmaPlot (SPSS 
Science). 
 
Thermal unfolding monitored by circular dichroism 
The far-UV CD spectra were measured using an Aviv62A DS (Lakewood, N.J.) 
circular dichroism spectrophotometer with a computer controlled Kryo-Thermat 650 
(Haake) water bath. The samples of wild-type PleD and the IS,all mutant at 10 µM 
were measured in a 50 mM Tris pH 8.0 buffer ±120 µM c-di-GMP. For PleD 
activation 1 mM BeCl2, 10 mM NaF and 10 mM MgCl2 were added to the buffer. The 
thermal stability of PleD was monitored by heating samples over a range of 10-75 °C 
at a rate of 30 °C/h in a water-jacketed cell with a 0.1 cm light path. The ellipticity at 
222 nm was recorded at 1 °C intervals, collecting data at each point for 3-6 s. The 
observed ellipticity θobs was normalized according to the equation: 
θnorm = (θobs - θmin) × 100 / (θmax - θmin),                 
whereby θmin and θmax are the ellipticities of unfolded and folded PleD, respectively. 
To determine the apparent TM of the unfolding, data were fit using the commercial 
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program SigmaPlot (SPSS Science) assuming a two-state transition between the 
folded and the unfolded protein. 
 
Analytical ultracentrifugation 
A Beckman-Coulter XL-A analytical ultracentrifuge was used for the experiments, 
which were conducted at 10 °C. Where appropriate protein samples were buffered 
either in the non-activating (10 mM HEPES pH 7.5, 100 mM NaCl) or the activating 
buffer (10 mM HEPES pH 7.5, 100 mM NaCl, 10% N-Methylformamide, 10 mM 
MgCl2, 1 mM BeCl2, 10 mM NaF). The measurements of the density of the non-
activating (1.005 g/cm³) and the activating buffer (1.012 g/cm³) were performed at 10 
°C with an Anton Paar DMA 4500 density meter. The buffer viscosity of 1.31 mPa × 
s was measured with a Brookfield DV-II cone-plate viscometer. The partial specific 
volume of the PleD samples at 10° C (0.734 cm³/g) was calculated using the amino 
acid sequence. All measurements were analyzed using the absorption coefficients of 
10190 M-1cm-1 at 275 nm and 3957 M-1cm-1 at 253 nm for wild-type PleD (MW = 
50447 Da), of 10189 M-1cm-1 at 275 nm and 3957 M-1cm-1 at 253 nm for the IS,all 
mutant (MW = 50192 Da) as well as of 14945 M-1cm-1 at 275 nm and 23700 M-1cm-1 
at 253 nm for c-di-GMP (MW = 690 Da). The sedimentation equilibrium experiments 
were performed at 12000 rpm with 20 µM wild-type or mutant PleD in the non-
activating and the activating buffers as well as with 20 µM wild-type or mutant PleD 
± 40 µM c-di-GMP in the activating buffer. Data collection was performed at 253 and 
275 nm after reaching the equilibrium (20 hours). Using two different wavelengths 
allowed the determination of the PleD concentration in presence of the light 
absorbing ligand c-di-GMP. The data analysis was performed with the DISCREEQ 
software (17,18). In short, fits were performed according to the review (19) equation 
[9], using the calculated molecular weights of six theoretical oligomeric species of 
PleD as constants. The monomer-dimer dissociation constants were calculated 
applying the law of mass action. 
 
Surface plasmon resonance 
The NTA Sensor Chips, the HBS-P and the HBS-EP buffers were purchased from GE 
Healthcare, NiCl2 and urea from Sigma-Aldrich. All experiments were conducted on 
a BIACORE 3000 (GE Healthcare) at 10 °C and a constant flow of 30 µl/min. The 
protein and the c-di-GMP samples were diluted in the running buffer (10 mM HEPES 
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pH 7.4, 0.15 M NaCl, 50 µM EDTA and 0.005% Surfactant P20). The activation of 
the sensor chips was performed reproducibly applying a 500 µM NiCl2 solution for 
one minute. The wild-type and mutant PleD samples (30 µg/ml) were immobilized in 
three of the four channels applying the protein solutions for one minute, resulting in a 
signal of approximately 1000 response units (RU). The protein-free channel was used 
as a reference channel. 
For the analysis of the analyte binding, c-di-GMP was applied at concentrations of 
50, 25, 12.5, 6.25, 3.125, 1.5625 and 0 (=buffer) µM, respectively. After each c-di-
GMP injection and simultaneous record of the association and dissociation phases the 
protein was striped from the chip applying an 8 M urea solution. The chip surface was 
activated by NiCl2 and the proteins were immobilized on the channels again before 
applying a new c-di-GMP sample. 
The analysis of c-di-GMP-protein binding kinetics was performed using the 
BIAevaluation software Ver. 4.1. The sensorgrams, subtracted by the response on the 
reference channel, were normalized with respect to the immobilized protein levels. 
The responses of the 0 µM c-di-GMP (= buffer) injections were subtracted from other 
sensorgrams prior to the performance of the fitting procedure. The processed 
sensorgrams were fitted using a simple 1:1 binding model with a global parameter for 
the drift. 
 
Calculation of dimer concentration  
The concentration of dimers [D] can be calculated from the absolute concentration 
[M0] knowing the dimerization dissociation constant KD using the following equation: 
[D] = 0.5 × [M0] + 0.125 × (KD - √(8 × [M0] × KD + KD2)),                  
whereby the concentration of monomers [M] can be derived from: 
[M0] = 2 × [D] + [M]. 
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Results 
 
Thermal unfolding of PleD monitored by CD 
Our recent publication has verified the crucial role of the secondary inhibition sites, 
IS,D2 and IS,DGC, in the inhibition process by site directed mutagenesis and enzymatic 
characterization (14). C-di-GMP mediated domain cross-linking should manifest 
itself in a higher rise of the protein stability compared to PleD that binds c-di-GMP 
solely to the primary I-site. 
Thermal unfolding of wild-type PleD monitored by CD at 222 nm in absence or 
presence of c-di-GMP (IP-IS,D2 cross-linking) reveals a TM increase of 2.8 °C in the 
ligand bound state (Figure 1A, Table 1). The bad fitting to the two-state model in the 
initial phase of the heat-denaturation, might represent unfolding of the single 
domains. Addition of c-di-GMP seems to decrease this atypical behavior. To 
investigate the effect of protein stabilization by c-di-GMP cross-linking IP and IS,DGC, 
which is observed in PleD dimers, the protein was activated by BeF3¯ •Mg2+. The 
activation process leads to destabilization of PleD that can be attributed to the Mg2+-
ions (Figure 1A). The subsequent addition of c-di-GMP to the activated PleD 
dramatically increases the TM value by 11.9 °C (Table 1). 
The mutation of the three arginine residues to alanine in the secondary I-sites 
deficient PleD mutant (R148A R178A R313A = PleD-IS,all) leads to a 
destabilization of the protein by 3.3 °C (Figure 1B). In contrast to the wild-type 
protein, addition of c-di-GMP increases the stability of the mutant to a much lesser 
amount in both states, the non-activated and the activated one (Table 1). Due to the 
absence of the secondary I-sites - disabling the domain cross-linking, this decreased 
stabilization effect must be attributed to the binding of c-di-GMP to the primary I-
site. 
Therefore, these results show stabilization of PleD by c-di-GMP binding to the 
primary I-site (a) and especially to the secondary I-sites (b). The later can be 
attributed to long range domain interactions. 
 
Investigation of the PleD dimerization process by AUC 
Dimerization of PleD is used as one of the regulatory mechanisms for this protein 
(14,15). Additionally, it is known that mutations in the IS,D2-site result in a 4-10 fold 
higher enzymatic activity compared to the wild-type protein (13,14). To rule out the 
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involvement of the secondary I-sites in dimerization of the protein as well as to 
elucidate the effect of c-di-GMP in this process we have performed sedimentation 
equilibrium AUC experiments with PleD wild-type and the IS,all mutant in non-
activating and activating (+BeF3¯ •Mg2+) conditions, respectively (Figure 2). Due to 
instability of PleD protein losses were detected during these experiments (Table 2). 
Under non-activating conditions, both, wild-type and mutant PleD are found 
exclusively in the monomeric state at a concentration of 20 µM (Table 2). Activation 
by BeF3¯ •Mg2+ leads to a monomer/dimer equilibrium that translates into a KD for 
dimerization of 10-15 µM for both wild-type and mutant PleD (Table2). Therefore, 
mutation of the IS,D2-site does not alter the dimerization process. 
Surprisingly, addition of c-di-GMP to activated wild-type or mutant reduced the 
dimerization KD by an order of magnitude in both cases (Table2). These results 
suggest stabilization of the dimerization in presence of c-di-GMP independent of the 
secondary I-sites. Unfortunately, we could not perform similar experiments with the 
non-activated protein samples, for which much higher protein and c-di-GMP 
concentrations are needed. Due to the high absorbance of c-di-GMP, utilization of 
higher concentrations is not feasible. 
In these experiments c-di-GMP was added in non-saturating concentrations to the 
PleD samples, due to its very high extinction coefficient. Nevertheless, the calculated 
protein-ligand stoichiometry (Table 2) indicates increased binding of c-di-GMP to 
PleD wild-type than to the IS,all mutant. 
 
Determination of thermodynamic and kinetic rate constants of PleD by surface 
plasmon resonance (SPR) 
ITC experiments have shown binding of two molecules c-di-GMP per PleD protomer 
(15). Additionally, the crystal structures of PleD show a c-di-GMP dimer cross-
linking the primary with one of the secondary I-sites (12,14). 
Two ways of binding of these two c-di-GMP molecules are conceivable. They could 
bind sequentially as monomers or as a dimer.  
We have used the SPR technique to get further insight into the binding process. 
Association phases of 90 s and dissociation phases of 300 s of c-di-GMP binding to 
the PleD wild-type as well as to the mutants R313A (IS,DGC), R148A R178A (IS,D2) 
and IS,all were recorded (Figure 3). 
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The fittings of the obtained curves using the nominal concentrations of applied c-di-
GMP and the fitting algorithms of the BIAevaluation software for a 1:1 binding or 
sequential binding of two c-di-GMP molecules resulted in very bad fits (2 > 1). 
The rich oligomeric behavior of c-di-GMP is well known, in particular to form dimers 
with intercalated bases (20,21). Due to the utilization of extremely high 
concentrations (millimolar range) in these studies the dimerization KD was not 
determined (21). Recent NMR studies performed at lower c-di-GMP concentrations 
suggest a value of about 50 µM for the KD (M.Allan, unpublished data). 
This dimerization KD can be used for the concentration calculations of the monomeric 
and the dimeric species out of the nominal concentrations (see Materials&Methods). 
If in such a way calculated concentrations of monomeric c-di-GMP are used in the 
previously described fittings, the fits do not improve (data not shown). 
On the other hand, performance of the fitting procedures with the calculated dimer 
concentrations of c-di-GMP (dimerization KD = 50 µM) using a simple 1:1 binding 
algorithm leads to trustable fits (2 = 0.1 for PleD wild-type) (Figure 3). The quality 
of the fits deteriorated, if for the assumed dimerization KD of c-di-GMP, values below 
10 µM or above 100 µM were used.  
Although binding of c-di-GMP monomers and dimers could apply in parallel we do 
not approach this option. The very low propensity of such a scenario, the inability to 
prove the correctness of a corresponding fit, taking in account too many variables, 
and the very good fits with c-di-GMP dimers as the binding species let us discard this 
possibility. Thus, we propose that c-di-GMP binds as a dimer to PleD with a 
dimerization KD of 50 µM for c-di-GMP. The binding is hereby very strong, with an 
apparent KD of 25 nM (Table 3). A c-di-GMP solution with the nominal 
concentration of 1.2 µM contains this dimer concentration. 
To elucidate the interaction properties between PleD and [c-di-GMP]2 regarding the 
secondary I-sites, the SPR experiments were conducted with the IS mutants (Table 3). 
The absence of the IS,DGC (=R313A) has almost no effect on the apparent binding 
properties. Whereas, the absence of the IS,D2 (=R148A R178A) or both secondary I-
sites results in decreased binding with a four-fold higher dissociation constant.  
We have tried to estimate the effect of the subsequent cross-linking process fitting the 
curves to a “two-state reaction” algorithm of the BiaEval software assuming the 
following reactions: 
(1) (c-di-GMP)2 + PleD  PleD-(c-di-GMP)2 
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(2) PleD-(c-di-GMP)2  PleD*-(c-di-GMP)2, 
whereby the first reaction represents the binding of c-di-GMP dimers to the primary 
I-site, and the second reaction represents the cross-linking mechanism. The quality of 
the fits stayed hereby unchanged. Additionally, the obtained rate constants for the 
second reaction were negligible in comparison to the ones of the first reaction and are 
therefore not trustable (data not shown). The kinetic parameters for a potential second 
step can therefore not be derived by SPR. 
Thus, binding of c-di-GMP to the immobilized PleD is not strongly affected by 
secondary I-sites in the non-activated state i.e. monomeric, where c-di-GMP 
dependent cross-linking can take place solely between IS,D2 and IP. 
 
Enzymatic activity of the PleD R390S mutants 
The fact that c-di-GMP is to our knowledge the first inhibitor, working as 
domain/protein cross-linker, and that lack of the secondary I-sites doesn’t result in the 
complete abolishment of the inhibition (14) led us investigate this regulatory 
mechanism in closer detail by the means of site directed mutagenesis. 
In case of PleD the primary I-site is composed of the strongly conserved RxxD motif 
and the arginine 390. Unfortunately, mutations in the RxxD motif result in proteins 
lacking any enzymatic activity (13) and are therefore inconclusive. 
We have mutated arginine 390 of the primary I-site to a serine in the wild-type and in 
the secondary I-sites deficient (R148A R178A R313A) background to investigate the 
role of this residue in the process of inhibition. 
The strong involvement of the primary I-site mutant R390S in the c-di-GMP 
dependent inhibition is evident in the strongly increased Ki (140 µM) (Figure 4). The 
combination of this mutation with the IS,all mutant (=> IS,all/R390 mutant) leads to a 
complete independence from the regulatory effect of c-di-GMP. Additionally, we 
couldn’t detect any binding of c-di-GMP (c = 100 µM) by this mutant using the SPR 
technique (data not shown). To our surprise this mutant doesn’t exhibit anymore the 
higher enzymatic activity that was observed with the IS,all mutant (Figure 4).  
Thus, R390 of the primary I-site turns out to be strongly involved in c-di-GMP 
binding and in the inhibitory process. 
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Discussion 
 
C-di-GMP binds as a dimer to the DGC PleD 
One of the interesting aspects concerning the second messenger c-di-GMP is its 
ability to form multimers (20,21). Due to intracellular concentrations in the sub-
micromolar range (7,22,23) only monomeric and dimeric forms of c-di-GMP seem to 
predominate in-vivo. Moreover, both species are relevant for the signal transduction 
process. 
Whereas PDEs were shown to bind c-di-GMP in the monomeric form (24), the crystal 
structures of PleD and WspR have shown c-di-GMP dimers bound to the allosteric 
sites of the DGCs (12,14,25). In contrast to the general opinion of sequential binding 
of c-di-GMP monomers to the allosteric sites of DGCs, our experiments show c-di-
GMP dimers as being the relevant species in this process. The very low dissociation 
constant between (c-di-GMP)2 and PleD (25 nM) is actually in near agreement with 
the previously described Ki and KD of 0.6 µM c-di-GMP (12,15). Assuming a 
dimerization KD of 50 µM (M. Allan, unpublished data) a 0.6 µM c-di-GMP solution 
consists of 7 nM dimers. 
Allosteric regulation of DGCs by c-di-GMP dimers might additionally lead to a 
higher stringency of the inhibitory process. At nanomolar levels of c-di-GMP, which 
are normally found in bacterial cells (26,27), the DGCs are almost unaffected by c-di-
GMP due to very low concentrations of (c-di-GMP)2. The rise in the overall c-di-
GMP concentration from ~50 nM to ~5 µM (the physiological levels) leads to an 
quasi exponential increase in the (c-di-GMP)2 levels (Figure 5). Due to a very low 
binding KD to PleD, inhibition by (c-di-GMP)2 must have an exponential character, 
accordingly. This is in agreement with the regulatory role of this process, which 
should shut down DGCs at higher cellular levels of the second messenger. 
The future has to show which of the described c-di-GMP species play a role in the 
downstream signaling processes. Both species, monomers and dimers, are imaginable 
to be involved in these, according to the expected downstream effects. If the c-di-
GMP sensor is a part of a signaling pathway responding to low concentrations of the 
second messenger, the sensor may recognize monomers. The signal circuitries 
responding to higher c-di-GMP concentrations might rely on c-di-GMP sensors, 
which recognize only dimers. Such situation could actually explain the structural 
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observation of PilZ domain proteins in complex with monomeric (28) and dimeric 
(29) c-di-GMP. 
 
Regulation of PleD by the “domain-immobilization” mechanism 
The discovery of two separate cross-linking modes of PleD by c-di-GMP dimers 
binding to one primary and one of the two secondary I-sites, respectively, as well as 
the resulting regulation by the “domain-immobilization” mechanism has often been 
met with skepticism. Although more and more structural evidences appear 
(12,14,25,28), which affirm the relevance of the secondary I-sites for the binding of 
c-di-GMP, the main scientific opinion states the RxxD motif of the IP as the sole c-di-
GMP binder, resulting in protein inhibition by unknown conformational changes 
(13,26). 
According to our results the IS,all/R390 PleD mutant having only the RxxD motif left 
for interaction with c-di-GMP doesn’t bind the second messenger anymore. In line 
with this, the IS,all/R390 mutant shows no product inhibition. In addition to the PleD-c-
di-GMP complex structures we have now the biophysical evidence that R390 is part 
of the IP-site interacting directly with c-di-GMP. Other DGCs having no arginines at 
the corresponding position probably utilize other near-by residues in combination 
with the well conserved RxxD motif to bind c-di-GMP. Thus, although the RxxD 
motif stays the unchallenged indicator of allosterically regulated DGCs (13), its sole 
presence is not sufficient for the binding process. 
The surprising AUC result that binding of c-di-GMP to the IP-site enhances the 
dimerization of PleD independently of the IS-sites must be verified and the putative 
mechanism has to be characterized in the future. It is imaginable that such protein-
ligand interaction leads to a reduced flexibility of the linker-attached GGDEF domain 
or keep it out of the Rec1-Rec2 dimer interface, allowing a higher stochastic 
propensity for the Rec domains to form the (Rec1-Rec2)2 stem dimer. 
Although our SPR results indicate a strong preference of the IP-site for binding c-di-
GMP, the thermal unfolding experiments verify a crucial role for the secondary I-sites 
in the c-di-GMP dependent protein stabilization, especially in the activated state. 
Thus, the allosteric product regulation mechanism is initiated by a highly affine 
binding of c-di-GMP dimers to the IP followed by an interaction with the secondary I-
sites cross-linking the involved domains.  
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The subsequent interaction of ‘captivated’ c-di-GMP with the secondary I-sites, at 
least with IS,D2, must be (much) lower in affinity than binding to the IP, since the 
dissociation constants of the wild-type PleD and the IS,all mutant differ only by a 
factor of ~4. Missing improvements in the quality of the fits, which additionally take 
the cross-linking mechanism in account, also speaks for this conclusion. No 
conclusions can be drawn concerning the IP-IS,Dgc cross-linking mode from these SPR 
experiments, due to the incompatibility of the activation procedure with this 
technique. On the other hand the R390S PleD mutant, which binds c-di-GMP 
between the RxxD motif and the secondary I-sites, exhibits an extreme rise in the Ki. 
This confirms the lower binding affinity of all secondary I-sites in comparison to the 
very strong binding affinity of the IP. 
According to these findings we were mistaken in our recent publication describing the 
secondary I-sites mutant IS,all as partially inhibitable (14). The ~ 4-10 fold higher 
activity of this mutant compared to the wild-type protein is due to the mutations of 
arginines 148 and 178 to alanines as was described before (13). Our AUC data clearly 
demonstrate the independence of this ‘activation’ mechanism from the dimerization 
process. Addition of c-di-GMP to the IS,all mutant results in an asymptotic decrease 
of the enzymatic activity that converges to a rate that is equal to rate of the not-
inhibited wild-type PleD. Surprisingly, elimination of arginine 390 in this background 
(= IS,all/R390) abolishes completely the described activation, but also the observed 
‘inhibition’ by c-di-GMP. The enzymatic activity of this quadruple mutant is equal to 
the activity of the not-inhibited wild-type PleD and of the inhibited IS,all. Therefore, 
addition of c-di-GMP to the IS,all mutant seems to counteract the observed increased 
activity. We propose that R390 is involved in this activation process, but can be 
withdrawn from it by binding c-di-GMP to the IP-site. 
Summing up, we have shown that: (I) c-di-GMP binds in its dimeric form to PleD; 
(II) the recruiting of (c-di-GMP)2 to PleD is performed mainly by the IP-site; (III) for 
a IP-c-di-GMP interaction a complete IP-site is needed, namely R390 and the RxxD 
motif; (IV) the IP-c-di-GMP interaction doesn’t result in inhibition; (V) cross-link of 
c-di-GMP loaded IP-site with one of the secondary I-sites causes the inhibition of 
PleD. Further investigations must have the aim to quantify the thermodynamic and 
kinetic binding parameters of the interaction between the c-di-GMP bound to the IP-
site and the secondary I-sites to gain the complete understanding of the allosteric 
product inhibition process. 
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Figure legends 
 
Figure 1. Thermal unfolding profiles of PleD wild type (A) and the PleD-IS,all 
mutant (B) 
The thermal stability was assayed of non-activated (- c-di-GMP [black], + c-di-GMP 
[red]) and BeF3¯ •Mg2+-activated protein (- c-di-GMP [green], + c-di-GMP [yellow]). 
The unfolding of wild type protein was additionally measured in presence of Mg2+-
ions [blue]. The elipticity at 222 nm was monitored as a function of temperature. The 
data have been fitted with a two-state model (continuous lines).  
 
Figure 2. Analysis of the quaternary state of PleD by sedimentation equilibrium AUC 
Representative plots of the SE runs of PleD wild-type (circles) and PleD-IS,all 
mutant (triangles). (A) Absorbance of BeF3¯ •Mg2+-activated protein samples in 
presence of c-di-GMP [red] measured at 253 nm. (B) Absorbance of non-activated 
[blue] and activated protein samples (- c-di-GMP [green], + c-di-GMP [red]) 
measured at 275 nm. The corresponding plots of the residuals are shown at the upper 
panels (wild-type as lines, mutant as dots). The black lines represent the global fits to 
an equilibrium model. 
 
Figure 3. Analysis of c-di-GMP binding to immobilized PleD samples by SPR 
Representation of association and dissociation phases of c-di-GMP at nominal 
concentrations of 50, 25, 12.5, 6.25, 3.125 and 1.5625 µM, respectively, binding to 
immobilized PleD wild-type (A), the IS,Dgc mutant (C), the IS,D2 mutant (E) and the 
IS,all mutant (G). The fits of the data are shown as stripped red lines. The 
corresponding residuals are shown in the lower panels (B, D, F and H). 
 
Figure 4. Analysis of c-di-GMP dependent inhibition of PleD 
Plots of the specific activity of PleD wild-type (blue), the IS,DGC mutant (black), the 
IS,D2 mutant (red), the IS,all mutant (green), the R390S mutant (magenta) and the 
combined IS,all/R390 mutant (yellow) as a function of c-di-GMP concentrations. Note, 
the ordinate is represented logarithmically! 
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Figure 5. Simulation of dimeric (and monomeric) c-di-GMP concentrations at 
physiological concentrations of c-di-GMP (overall) 
The concentrations of the monomeric (blue) and the dimeric (red) species of c-di-
GMP were calculated according to the equation given in the Materials&Methods 
section assuming a dimerization KD of 50 µM. Note the different scaling of the 
concentrations of both species! 
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Table 1: Thermal unfolding of PleD samples 
 
 
 
Table 2: Results of SE AUC experiments with PleD samples 
* The KD was calculated neglecting the higher oligomer species 
sample apparent TM (°C) 
PleD wt 48.2 ± 0.6 
PleD wt + c-di-GMP 51.0 ± 0.3 
PleD wt + Mg2+ 36.2 ± 0.5 
PleD wt + BeF3

• Mg2+ 33.6 ± 0.7 
PleD wt + BeF3

•Mg2+ + c-di-GMP 48.1 ± 1.1 
PleD IS,all 44.9 ± 0.6 
PleD IS,all + c-di-GMP 44.4 ± 0.5 
PleD IS,all + BeF3

• Mg2+ 35.8 ± 0.5 
PleD IS,all + BeF3

• Mg2+ + c-di-GMP 41.3 ± 0.6 
abundance (%) 
sample 
protein 
concentration 
in solution 
(µM) monomer dimer multimers 
dimer. KD* 
(µM) 
protein: 
ligand 
stoichio-
metry 
PleD wt 10.81 100 0 0 - - 
activated PleD 
wt 8.44 66.9 32.5 0.6 11.6 - 
activated PleD 
wt + c-di-GMP 10.86 11.6 85.1 3.3 0.16 1:1.17 
PleD IS,all 9.91 97.6  2.4 - - 
activated     
PleD IS,all 
8.44 68.1 25.6 6.3 15.3 - 
activated      
PleD IS,all                   
+ c-di-GMP 
2.59 21.7 58.6 19.7 0.15 1:0.46 
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Table 3: SPR derived kinetic and thermodynamic rate constants 
 
 
 
 
Figure 1 
 
 
 
 
Figure 2 
 
sample kon (s-1 M-1) koff (s-1) KD (nM) 
PleD wt 7.85 ± 0.04 × 104 1.96 ± 0.02 × 10-3 25 ± 1 
PleD IS,DGC 8.92 ± 0.06 × 104 5.49 ± 0.02 × 10-3 61 ± 2 
PleD IS,D2 3.28 ± 0.04 × 104 3.71 ± 0.06 × 10-3 110 ± 6 
PleD IS,all 3.72 ± 0.04 × 104 4.03 ± 0.05 × 10-3 108 ± 5 
A         B 
A          B 
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Abstract 
Most diguanylate cyclases are composed of a C-terminal catalytic GGDEF domain 
and N-terminal dimerization/regulatory domains. A minor class of diguanylate 
cyclases shows non-annotated sequences of various lengths at its N-termini. These 
proteins are therefore called ‘stand-alone’ DGCs. We have analyzed two of these 
proteins, DgcA and DgcB from Caulobacter cescentus. Both are forming permanent 
N-terminal ‘domain’-mediated dimers. In contrast to DgcA, the N-terminal ‘domain’ 
of DgcB seems additionally to have a regulatory function. 
Another regulatory mechanism utilized by diguanylate cyclases is the allosteric 
product inhibition. Hereby, the main theory postulates binding of c-di-GMP to the 
RxxD sequence motif in the GGDEF domain. DgcA, which possesses these residues,
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was previously shown to be inhibitable. DgcB, on the other hand, lacks the RxxD 
motif. Nevertheless, we could show inhibition of DgcB by c-di-GMP. SPR and ITC 
experiments show binding of c-di-GMP dimers to a non-defined allosteric site. 
Additionally, SEC-MALS and AUC experiments demonstrate formation of DgcB 
tetramers in presence of c-di-GMP. 
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Introduction 
 
The role of the eubacterial second messenger bis-(3’-5’)-cyclic dimeric guanosine 
monophosphate (c-di-GMP) stayed for a long time unrecognized (1). The interest in 
this signaling pathway awoke with the realization that the c-di-GMP producing 
diguanylate cyclases (DGCs) and degrading phosphodiesterases (PDEs) are 
ubiquitously coded in the genomes of bacteria (2). The second messenger gained 
further attention by emerging evidences showing involvement of c-di-GMP in several 
crucial cellular functions. It regulates the transition between the sessile and the motile 
states in bacteria, controlling biofilm formation (3-5) on the one hand and virulence 
of pathogens on the other (6-8). Additionally, it was shown to be involved in control 
of the cell cycle (9) and antibiotic biosynthesis (10). 
Despite the high versatility of cellular responses that are regulated by c-di-GMP, the 
number of identified direct downstream targets stays relatively low. The second 
messenger is known to interact with proteins containing the PilZ domain (11,12), but 
the downstream effects of this binding is not resolved, yet. Most recently c-di-GMP 
was shown to play a role on the DNA/RNA level interacting with riboswitches (13). 
The few identified effectors of c-di-GMP are facing an abundance of DGCs and 
PDEs, which are often present in high numbers in a single bacterial species. The 
enzymatic activity of DGCs, the biosynthesis of c-di-GMP consuming two molecules 
GTP, is performed by the GGDEF domains, named according to the conserved 
consensus motif of the active site. The DGCs were shown to act as dimers (14) 
forming a single active site at the interface of the GGDEF domains. These results are 
in agreement with the fact that the GGDEF domains bind only one GTP molecule 
(15,16). 
Enzymatic activity of DGCs is highly regulated. One of the regulatory mechanisms is 
the allosteric product inhibition of DGCs. Crystal structures of PleD (15,16) and 
WspR (17) have shown binding of c-di-GMP dimers to an RxxD motif in the GGDEF 
domain (referred to as the primary I-site) and to additional arginines (secondary I-
sites) from another domain. It was proposed that such relative domain immobilization 
prevents the GGDEF domains to form a functional active site. The RxxD motif is 
conserved in the DGCs and was, therefore, postulated to be an indicator of DGCs, 
which are regulated by product inhibition (18). 
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Dimerization of DGCs is used as another regulatory mechanism. Many DGCs use N-
terminal domains for dimerization, e.g. response regulator receiver domains (Rec). In 
case of PleD dimerization occurs upon phosphorylation of the N-terminal Rec domain 
(14,16). 
In addition to the main class of DGCs consisting of C-terminal GGDEF domains and 
N-terminal regulatory dimerization domains, a high number of GGDEF domain 
proteins contains N-terminal ‘domains’ of ~ 25 to 500 amino acids length. These 
‘domains’ are not annotated. Therefore, such proteins were misleadingly named 
‘stand-alone’ DGCs. Two contradicting theories are attributed to the function of these 
N-terminal domains. One assigns no specific function to them. This leads to a 
theoretical ability of the GGDEF domains to dimerize. The other theory sees in them 
the necessary dimerization domain resulting in formation of permanent DGC dimers. 
The last theory implies the inability of the GGDEF domains to dimerize on their own. 
We have analyzed, biochemically and biophysically, two of such ‘stand-alone’ DGCs 
from C. crescentus, DgcA and DgcB. According to the present RxxD motif, DgcA 
was shown to be regulated by product inhibition (18). DgcB misses the RxxD motif 
and is therefore believed to be unaffected by product inhibition. 
In this study we have tried to answer the following questions. (I) What function could 
the N-terminal ‘domains’ have in the ‘stand-alone’ DGCs? (II) Are the GGDEF 
domains able to dimerize by their own or do they require N-terminal dimarization 
domains? (III) Several ‘stand-alone’ DGCs miss the RxxD motif like DgcB. Are 
these proteins permanently active, or do they utilize a distinct regulatory mechanism? 
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Materials and Methods 
 
Expression and Purification 
Instructions of DNA construct generation can be provided upon request. C-terminally 
His6-tagged versions of full-length DgcA, ∆DgcA (aa 83 – 237) and full length DgcB 
were overexpressed in E.coli BL21(DE3)pLysS (Novagen) strain. Cells carrying the 
appropriate plasmid were grown in Luria Broth (LB) media supplemented with 
ampicillin (100 µg/ml) and chloramphenicol (20 µg/ml). Induction of protein 
expression was performed adding IPTG to a final concentration of 0.5 mM. Clarified 
crude extracts were loaded on a HP HisTrap column (GE Healthcare) using 20 mM 
HEPES pH 7.5, 100 mM KCl, 20 mM imidazole as loading buffer. Elution of His6-
tagged proteins was performed raising the imidazole concentration. Concentrated 
protein samples were applied to the Superdex200 HR26/60 size-exclusion-
chromatography (SEC) column using 20 mM HEPES pH 7.5, 100 mM KCl as 
running buffer. 
Separation of c-di-GMP from DgcB was accomplished by a subsequent SEC run 
keeping the protein concentration below 5 mg/ml. 
The phosphodiesterase YahA was purified according a published protocol (19) and 
was a generous gift from A. Basle (University of Basel, Switzerland). 
 
Diguanylate cyclase activity assay 
Enzymatic experiments with DgcA, ∆DgcA and DgcB were performed in a 20 mM 
Tris/HCl pH 8.0, 100 mM NaCl buffer at 1.6, 2.3 and 26 µM protein concentration, 
respectively, measuring the concentration of the second DGC product pyrophosphate. 
Degradation of pyrophosphate to phosphate was performed by the pyrophophatase. 
Detection of the phosphate using a coupled spectrophotometric assay is described 
elsewhere (15). Where necessary, PDE YahA (2 mg/ml) was added to prevent 
product inhibition of the DGCs. Measurement of DgcB inhibition was performed 
using apo-protein that was incubated with c-di-GMP (10, 25, 50, 100 µM) for at least 
thirty minutes prior to adding the substrate, GTP (c = 500 µM). 
 
Isothermal titration calorimetry 
Buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM MgCl2, 2 mM CaCl2) 
equilibrated protein and ligand solutions were thoroughly degassed at 25° C prior to 
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the performance of the experiments. Determination of dissociation constants of c-di-
GMP and GTPS binding to DgcB was conducted using a VP-ITC isothermal 
titration calorimeter (Microcal, Northhampton MA). Experiments were performed at 
25° C with c-di-GMP (120 µM) or GTPS (200 µM) in the syringe and DgcB (5 µM) 
in the cell. For the competition studies DgcB was saturated with the appropriate 
ligand at a concentration of 200 µM prior to the injection into the cell. To ensure 
complete re-equilibration of the solutions, delay between sequential injections was 
kept at 5-10 min. The integrated titration peaks were fitted as described in (20). 
 
SEC-coupled multiangle light scattering (SEC-MALS) 
SEC-MALS experiments were carried out using the ÄKTApurifier (GE Healthcare) 
connected Superdex200 HR10/300 column (GE Healthcare), the three-angle static 
light scattering detector miniDAWN (Wyatt Technology Corporation) and the 
differential refractive index detector Optilab rEX (Wyatt Technology Corporation). 
Bovine serum albumin (Sigma) was used for normalization of the SEC-MALS 
hardware. Where appropriate, protein samples (100 µl) were incubated with c-di-
GMP for thirty minutes prior to the injection to the column. Measurements were 
performed at a flow rate of 0.7 ml/min. Concentrations of the eluted protein was 
monitored by the differential refractive index, which in combination with the light 
scattering signal was used for the molecular weight calculation using the program 
ASTRA5.3.  
 
Analytical ultracentrifuge (AUC) 
All experiments were performed at 10 °C on a Beckman-Coulter XL-A analytical 
ultracentrifuge with absorbance optics. The buffer was 10 mM HEPES, pH 7.5, 100 
mM NaCl for all protein samples. At 10 °C the density was 1.005 g/cm3, measured 
with an Anton Paar DMA 4500 density meter, and the viscosity was 1.31 mPas 
measured with a Brookfield DV-II cone-plate viscometer. The partial specific volume 
of DgcB at 10° C was calculated using the amino acid sequence. All calculations 
were performed using the absorption coefficients of 23968 M-1cm-1 at 280 nm and 
10592 M-1cm-1 at 253 nm for DgcB as well as of 12852 M-1cm-1 at 280 nm and 23700 
M-1cm-1 at 253 nm for c-di-GMP. Sedimentation velocity runs with DgcB (26 µM) ± 
c-di-GMP (60µM) were conducted at 40000 rpm and recorded at 280 nm. The data 
were analyzed with Sedfit (21). Sedimentation equilibrium experiments were 
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performed at 12000 rpm with 13 µM DgcB ± 40 µM c-di-GMP. Equilibrium was 
reached after 20 hours. Using two different wavelengths, 253 nm and at 280 nm, 
allowed the determination of the DgcB concentration in presence of the likewise light 
absorbing ligand c-di-GMP. The data were analyzed with DISCREEQ (22-24). In 
short, fits were performed according to the review (23) equation [9], using the 
calculated molecular weights of six theoretical oligomeric species of DgcB as 
constants. The dimer-tetramer dissociation constants were calculated applying the law 
of mass action. 
 
Surface plasmon resonance (SPR) 
All experiments were performed on a BIACORE 3000 (GE Healthcare). The HBS-EP 
and HBS-P buffers and the NTA Sensor Chips were purchased from GE Healthcare. 
NiCl2 and urea were obtained from Sigma-Aldrich. 
10 mM HEPES pH 7.4, 0.15 M NaCl, 50 µM EDTA and 0.005% Surfactant P20 was 
used as running and dilution buffer. The experiments were performed at a constant 
flow of 30 µl/min and at 10° C. The Sensor Chip NTA was reproducibly activated by 
addition of a 500 µM NiCl2 solution for one minute. DgcB was used at a 
concentration of 30 µg/ml and was immobilized on the chip applying the protein 
solution for one minute, resulting in a signal of approximately 1000 response units 
(RU). The interaction of c-di-GMP with DgcB in the association and the dissociation 
phases was performed applying the analyte to a reference channel and to the channel 
with the immobilized protein. The protein was striped with a 8 M Urea solution after 
each measurement cycle and was freshly immobilized on the chip prior to the 
application of the next c-di-GMP sample. Such procedure was performed due to a 
drifting baseline and a regeneration-prone binding of c-diGMP. 
Analysis of c-di-GMP binding was performed using the BIAevaluation software Ver. 
4.1. The reference channel subtracted sensorgrams were normalized according to the 
immobilized protein level. The sensorgram of injected 0 µM c-di-GMP (= buffer) was 
subtracted from all other sensorgrams prior to the performance of the fitting 
procedure. The curated sensorgrams were fitted using a simple 1:1 binding model 
with a global parameter for the drift. The maximum response upon binding of one 
molecule c-di-GMP per molecule DgcB, Rmax, was calculated according to the 
following equation: 
Rmax, c-di-GMP = RDgcB×(MW, c-di-GMP / MW, DgcB), 
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Where RDgcB is the amount of immobilized protein, MW, c-di-GMP and MW, DgcB are the 
molecular weights of c-di-GMP and DgcB, respectively. 
 
Estimation of the dimeric species concentration 
Concentration of the dimeric species [D] can be calculated from the total molar 
concentration [M0] when the dissociation constant KD is known using the following 
equation: 
[D] = 0.5 × [M0] + 0.125 × (KD - √(8 × [M0] × KD + KD2)),                  
whereby  
[M0] = 2 × [D] + [M]. 
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Results 
 
Sequence analysis of DgcA and DgcB 
Both proteins are composed of a C-terminal GGDEF domain and an N-terminal 
domain of unknown structure and functional role (Figure 1A). The PCOILS web 
server (25) predicts coiled-coil regions in the N-terminal domains of both proteins 
with a > 50% probability (DgcA – aa 49-80, DgcB – aa 80-123, aa 146-168). To 
predict the DGC activity as well as the product inhibition behavior GGDEF domain 
sequences of DgcA and DgcB were compared with sequences of structurally known 
DGCs WspR and PleD (Figure 1B). As PleD and WspR, DgcA and DgcB bear the 
DGC consensus motif GGDEF/GGEEF. Protein sequence of DgcA contains the 
RxxD motif that has been shown to be indispensable for the c-di-GMP dependent 
inhibition of the diguanylate cyclase activity (18). Consistent with the domain-cross-
linking mechanism (16) DgcA contains besides the primary I-site (RxxD motif) also 
an arginine (R110) of helix 0 representing a secondary I site candidate. In WspR, an 
arginine at an equivalent position is involved in binding of c-di-GMP (17). 
Additionally, the DgcA sequence shows an arginine (R103) two helical turns apart 
from R110 that could synergistically interact with c-di-GMP.  
The RxxD motif of DgcB is degenerated to APPR, but DgcB bears an arginine at an 
equivalent position to R103 of DgcA. According to the main role of the RxxD motif 
in binding c-di-GMP, the protein sequence analysis leads to the assumption that 
DgcB is unaffected by the allosteric inhibition process. Thus, the presented analysis 
suggests that both proteins are functional diguanylate cyclases and that DgcA might 
be allosterically regulated by c-di-GMP. 
 
The N-terminal domain mediates dimerization in DgcA 
Both, DgcA and DgcB, elute from size-exclusion chromatography (SEC) columns as 
dimers (results not shown for DgcA). To see whether the N-terminal domains are 
involved in dimerization, a dgcA construct coding for a mutant (∆DgcA = aa 83-237) 
that lacks the N-terminal domain was created. The correct fold of the resulting protein 
was assured by SPR experiments, showing similar c-di-GMP binding characteristics 
for the wild-type and the truncated versions of DgcA (Supplementary figure 1). As 
judged by SEC ∆DgcA is monomeric (results not shown) suggesting that the N-
terminal domain is responsible for dimerization of DgcA. Dimerization is a 
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prerequisite for DGC activity (14), therefore enzymatic activity of both proteins was 
measured. The analysis showed no enzymatic activity for ∆DgcA, whereas full-length 
DgcA shows a high specific activity for DGCs of 0.61 µM µM-1 s-1 (see next 
paragraph) (Figure 2A). 
 
Inhibition of DgcA and DgcB by c-di-GMP 
DGCs with an allosteric product binding site are known to co-purify in presence of c-
di-GMP (16). This is the case for DgcA and surprisingly also for DgcB. To be able to 
measure the enzymatic activity of ∆DgcA, DgcA and DgcB in absence of the 
inhibitory effect of c-di-GMP, measurements were performed in presence of c-di-
GMP degrading phosphodiesterase YahA. DgcA shows a much higher specific 
activity (0.61 µM µM-1 s-1) in comparison to DgcB (8.8×10-4 µM µM-1 s-1) (Figure 2).  
Inhibition of DgcA and DgcB by co-purified and enzymatically produced c-di-GMP 
can be observed in enzymatic assays lacking YahA (Figure 2). Separation of c-di-
GMP from DgcB can be achieved by SEC (HR16/60 Superdex 75) using protein 
samples of concentrations lower than 75 µM. The RxxD motif deficient DgcB (Figure 
1) is fully inhibitable (Figure 3), with a rather high IC50 value of 20 µM (at a protein 
concentration of 26 µM). 
 
Non-competitive inhibition of DgcB by c-di-GMP 
DgcB lacks the predicted c-di-GMP binding residues of the primary I-site (16,18). 
Nevertheless it is affected by product inhibition. To understand this molecular 
process, competitive binding studies were performed using substrate analogue and 
product. For the determination of the stoichiometry as well as of the KD-values (=Ki), 
isothermal titration calorimetry (ITC) technique was used. The integrated binding 
enthalpies of c-di-GMP added to DgcB resulted in readily fitable sigmoidal curves 
(Figure 4). Deviation from ideality was observed for the first 3-5 injections of c-di-
GMP, as reported before for PleD (14). To avoid complication of our fits by 
introduction of terms taking in account e.g. the multimerization state of c-di-GMP 
(26), the value of the first injection was excluded from the fit. To study, whether c-di-
GMP competes with the substrate for binding to the active site the non-hydrolysable 
substrate analogue GTPS was used as competitor (Figure 4B). Both, in presence and 
absence of GTPS, the dissociation constants of c-di-GMP were found to be virtually 
identical (0.66 ± 0.1 µM vs. 0.69 ± 0.1 µM). Both experiments show a stoichiometry 
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of 2 ± 0.4, which is in agreement with the presence of c-di-GMP dimers in structures 
of PleD and WspR (15-17,27).  
Similarly, binding of the substrate analogue was also not influenced by the presence 
of c-di-GMP. Injections of GTPS to apo and c-di-GMP incubated DgcB showed in 
both cases dissociation constants of 5 ± 3 M (Figure 4C).  
Thus, two molecules of c-di-GMP bind to an allosteric site of DgcB that is distinct 
from the active site. Binding of the inhibitor doesn’t influence substrate binding, and 
vice versa. 
 
Kinetics of c-di-GMP binding monitored by SPR 
To get further insights in the binding mechanism between c-di-GMP and DgcB 
surface plasmon resonance (SPR) experiments were performed instrument. Three 
main questions were pursued by this approach. Can the SPR technique verify a c-di-
GMP to DgcB binding ratio of 2:1, which was measured in solution by ITC? If so, 
does c-di-GMP bind to DgcB sequentially or as a dimer? And what are the kinetic 
parameters of this interaction? 
To avoid obstruction of the binding site and hampered flexibility immobilizing the 
protein via one of the randomly working covalent immobilization techniques, NTA 
sensor chips were used to immobilize the protein via its C-terminal His6-tag. Due to 
the dimeric nature of DgcB the immobilization occurs via both His6-tags, which was 
shown in other cases to increase the stability of the sensor chip trapped proteins (28). 
To obtain the binding stoichiometry steady state equilibrium experiments were 
conducted. For the purpose to reach the equilibrium an association phase of six 
minutes was chosen followed by a seven minutes long dissociation phase (Figure 5). 
Steady state responses were achieved after 250 seconds and were used to estimate the 
maximum response of the c-di-GMP binding to the trapped DgcB in a Scatchard plot 
analysis (Figure 6A). Analysis of the data resulted in an Rmax of 40.4 RU (slope =       
-KA, intercept = KA × Rmax. Comparison of this value with the expected Rmax of 20.5 
RU taking in account the response of the immobilized protein (1170 RU) and a 
theoretical protein-ligand stoichiometry of 1:1 suggests binding of two molecules c-
di-GMP per molecule DgcB. The non-linearity of the Scatchard plot (Figure 6A) 
clearly indicates that the 1:1 model is not adequate. 
This result enables c-di-GMP to be involved in several possible binding scenarios. 
Monomeric c-di-GMP molecules could bind independently to two distinct binding 
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sites on DgcB or they could bind sequentially to a single site. Another possibility is 
binding of a c-di-GMP dimer to a single site on DgcB. C-di-GMP is known to form 
multimers (26). Additionally, crystal structures of DGCs show I-site bound c-di-GMP 
dimers (15-17). Recent NMR experiments indicate a dimerization dissociation 
constant for c-di-GMP in the range of 10 to 50 µM (M. Allan, unpublished data). 
Although c-di-GMP might bind to DgcB as monomer and dimer at the same time, it is 
highly unlikely in our eyes. Additionally we tried to prevent any overfitting 
introducing too many variables. Therefore, the last binding scenario is not followed 
any further. 
To be able to identify the appropriate binding mode of c-di-GMP, kinetic 
measurements were performed. Analysis of the binding sensorgrams with eight 
distinct c-di-GMP concentrations was performed using the fitting algorithms of the 
BIAevaluation software estimating the kon and the koff values simultaneously (Figure 
7). A negative slope can be observed in the association phase using higher analyte 
concentrations, which lead to deviations between the measured data and the fits. 
Although a physiological relevance of the observed behavior cannot be excluded, e.g. 
conformational change in the analyte-bound state, a methodological or a technical 
malfunction seems to be more probable (29,30). 
Initially we have tried to fit the data not taking in account the dimerization of c-di-
GMP. Fittings of the monomeric c-di-GMP binding sequentially to a single site or 
independently to two distinct sites, which are represented by the ‘Bivalent analyte’ 
and the ‘Heterogeneous ligand – parallel reactions’ fitting algorithms in the 
BIAevaluation software, result in very bad predictions with too high χ2 values (χ2 > 
1.5) and in residuals, which are not tendency-free (Figure 7A, 7C, 7D). No drastic 
improvement could be observed performing the fits using the calculated 
concentrations of monomeric c-di-GMP at the assumed dimerization KD’s of 10 and 
50 µM (see Materials&Methods). The fits improved drastically using calculated 
concentrations of dimeric c-di-GMP with assumed dimerization KD’s of 10 and 50 
µM, respectively, and a 1:1 binding stoichiometry (Figures 7B, 7E, 7F). (The fits 
worsened using dimerization KD’s of 100 µM and 1 µM). 
These results are supported by the Scatchard plot analysis of the equilibrium 
experiments. Usage of the calculated c-di-GMP dimer concentrations instead of the 
nominal concentrations results in data points lying on a straight (Figure 6B). 
Additionally, the independently from each other derived KD values of c-di-GMP 
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dimers binding to DgcB from the equilibrium experiments and from the kinetics 
experiments (calculated from the rate constants) are almost identical (Table 1).  
Thus, c-di-GMP binds as a dimer to a DgcB protomer with a KD of 21 ± 14 nM 
assuming the c-di-GMP dimerization KD being in range of 10 to 50 µM. Such c-di-
GMP dimer concentration is present in a c-di-GMP solution with the nominal 
concentration of 0.51 ± 0.19 µM and 1.09 ± 0.38 µM, respectively (c-di-GMP 
dimerization KD = 10 and 50 µM, respectively). 
 
Binding of c-di-GMP induces tetramerization of DgcB 
SEC elution profiles of DgcB showing two distinct peaks indicate propensity of DgcB 
to form higher oligomers. To analyze this behavior SEC-MALS experiments were 
performed. To take the dilution of proteins during the SEC in account the 
concentration of protein was measured at the SLS detector by a refractive index 
diffractometer (Table 2). The obtained molecular masses indicate presence of dimeric 
and tetrameric DgcB species (Table 2). Measurements of apo DgcB at three different 
concentrations of 26, 390 and 676 µM (initial!), respectively, show appearance of 
tetramers at rather high, non-physiological concentrations (Figures 8A, 8C and 8E, 
Table 2).  
To see whether c-di-GMP has any influence on the quaternary state of DgcB, SEC-
MALS experiments were carried out with DgcB samples, which were preincubated 
with three fold higher concentration of c-di-GMP. The buffer was not supplemented 
with c-di-GMP to save costs. Thus, complex dissociation during the chromatography 
run had to be expected. C-di-GMP complexed DgcB was assayed at two different 
initial concentrations (26 and 390 µM, respectively) (Figures 8B and 8D, Table 2). 
Indeed, both runs show dissociation of c-di-GMP from the protein, which can be 
identified by UV signal following peak 1. At lower protein concentration c-di-GMP 
completely separates from protein and elutes as a separate peak at the total column 
volume. Therefore, this protein sample shows the elution profile of apo-protein due to 
complete separation of c-di-GMP during the SEC run. C-di-GMP is also ablating 
from DgcB used at the higher concentration (390 µM, initially), which is indicated by 
the tailing off of the UV-signal, but the nucleotide doesn’t completely dissociate from 
the protein. In contrast to the measurements of the apo-protein, which show co-
presence of dimeric and tetrameric DgcB species (samples of 390 and 676 µM), the c-
di-GMP preincubated protein (sample of 390 µM) is entirely tetrameric. Thus, apo-
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DgcB shows a propensity to form tetramers at non-physiological concentrations 
(31,32), whereas addition of c-di-GMP strongly reduces the KD of tetramer-dimer 
equilibrium. 
 
Quantification of c-di-GMP induced tetramerization of DgcB monitored by analytical 
ultracentrifugation (AUC) 
The effect of c-di-GMP inducing a shift in the DgcB dimer-tetramer equilibrium to 
lower concentrations was investigated using apo- and c-di-GMP saturated DgcB 
samples in the sedimentation equilibrium AUC experiments (Figure 9). Although 
DgcB is stable at concentrations used for this experiment, all AUC runs show protein 
losses due to aggregation, especially in presence of c-di-GMP. Neglecting the higher 
aggregates apo-DgcB is quasi dimeric (Table 3). In contrast, the c-di-GMP saturated 
DgcB sample reveals a dimer-tetramer equilibrium with a dissociation constant of 
0.02 µM. Consistent with the ITC and SPR results, the AUC experiment yields a 
1:1.8 stoichiometry between DgcB and c-di-GMP. 
To monitor the influence of c-di-GMP on the hydrodynamic parameters of DgcB, 
sedimentation velocity AUC experiments were conducted (Figure 10). Addition of c-
di-GMP turns out to influence the shape of both, dimeric and tetrameric, DgcB 
species (Table 4). Binding of c-di-GMP to DgcB results in modification of the axial 
ratio that is equivalent to elongation of the protein dimers. Increased spheroid a/b 
ratio of DgcB tetramers in comparison to the dimeric species indicates further 
elongation of the protein molecules. 
 
Activation of DgcB by an unknown effector (small ligand) 
The specific activity of DgcB decreases with a simultaneous release of phosphate as 
measured by a photometric assay (33). A four times lower enzymatic activity is 
observed two days after the purification compared to measurements with freshly 
purified DgcB. The protein is stable at 4 °C for weeks retaining its reduced enzymatic 
rate. Addition of phosphate doesn’t restore the specific activity and also no specific 
binding can be detected by ITC (data not shown). Mass analysis of DgcB samples 
either treated or not with alkaline phosphatase yields identical masses. Therefore, 
activation by protein phosphorylation can be ruled out. The released phosphate must 
be part of a bigger and rather instable ligand, which must have a very low binding KD. 
Since the well studied GGDEF domain is not known to interact with activators, it 
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must be a feature of the N-terminal dimerization domain. Further experiments are 
needed to elucidate the identity of this activator. 
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Discussion 
 
Inability of GGDEF domains to dimerize autonomously 
Cyclization of two GTP to a single c-di-GMP molecule by DGCs poses several 
requirements on this class of enzymes. Several studies have shown the necessity of a 
dimeric state for DGCs to be enzymatically active (14,34). This is in agreement with 
X-ray structures of DGCs showing GGDEF domains being able to bind only one 
substrate molecule (16). One of the main questions has always been – are GGDEF 
domains able to form dimers by themselves and so to produce c-di-GMP 
independently of associated regulatory domains? 
Most proteins bearing the GGDEF domain possess regulatory dimerization domains 
(e.g. REC, PAS, PAC, GAF), transmembrane domains or both. On the other hand 
there are several GGDEF domain proteins with non-annotated N-terminal domains of 
~ 25 to 500 aa length like DgcA and DgcB from C. crescentus. Although it is 
tempting to consider these as ‘GGDEF domain stand-alone proteins’, in case of DgcA 
and DgcB these N-terminal segments turn out to be involved in the dimerization 
process. Deletion of the N-terminal segment in DgcA resulting in a real ‘GGDEF 
domain stand-alone protein’ disables the dimer formation and therefore also the 
enzymatic activity of this protein. 
The example of the two so-called ‘stand-alone DGCs’, DgcA and DgcB, reveals at 
least two different functions for the N-terminal parts of these proteins. In DgcA the 
role of the N-terminal segment is dedicated to formation of permanent protein dimers. 
Proteins like DgcA are regulated solely by its product c-di-GMP. In case of DgcB 
preliminary experiments indicate a regulatory role for the N-terminal ‘domain’ 
besides its function in dimerization.  
It stays questionable whether there are true stand-alone DGCs at all and what function 
they might have. Interestigly there are no proteins in the SMART database (35) 
beginning N-terminally with a GGDEF domain. All of the so-called ‘stand-alone’ 
DGCs exhibit at least ~ twenty not-annotated amino acids in front of their GGDEF 
domains. 
 
Regulation of DgcA and DgcB by c-di-GMP 
Besides dimerization dependent regulation many DGCs are regulated through 
allosteric inhibition by their product c-di-GMP. The same has been observed for 
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DgcA, which is in agreement with the presence of primary and secondary I-sites in its 
amino acid sequence. Mutation studies have shown the necessity of the primary I-site 
RxxD motif for product inhibition in this protein (18). Our comparative sequence 
analysis shows presence of two arginins in the putatative secondary I-site. One of 
these residues at a topologically identical position in WspR was shown to interact 
with c-di-GMP (17). Therefore, inhibition of DgcA via cross-linking of the GGDEF 
domains is likely. 
Non-competitive inhibition of DgcB that possesses a degenerated RxxD motif on the 
other hand contradicts the general opinion of the primary I-site’s RxxD motif to be 
indispensable for c-di-GMP binding. This result is even more puzzling regarding the 
binding properties of c-di-GMP. The similar Ki/KD values of c-di-GMP binding to 
DgcB, PleD (14) and DgcA (18) as well as binding of c-di-GMP in dimeric form to 
DgcB and PleD (14,16, P.Wassmann unpublished data) suggest a similar binding site 
in all three proteins. This would implement binding of c-di-GMP to the modified 
RxxD motif (APPR). The consequence hereby would be binding of c-di-GMP to 
primary I-sites, which are lacking the exclusive RxxD motif. This would result in an 
extended number of c-di-GMP regulated DGCs. Mutational studies might prove this 
idea. 
Additionally, DgcB exhibits c-di-GMP induced tetramerization. Our results show for 
the first time proofs for c-di-GMP induced protein inhibition by an intermolecular 
cross-linking mechanism. We propose in analogy to the intramolecular cross-linking 
mechanism that was observed in PleD (16) inhibition by GGDEF domain 
immobilization. The question arises how does c-di-GMP manage to stabilize the 
DgcB tetramers? Binding of c-di-GMP dimers to DgcB in a 1:1 stoichiometry implies 
binding of four c-di-GMP dimers to a DgcB tetramer. The same stoichiometry was 
observed in solution (AUC and ITC) assaying DgcB tetramers as well as in SPR 
experiments with immobilized protein that cannot tetramerize. Binding of c-di-GMP 
between identical sites in a DgcB tetramer should result in a decreasing stoichiometry 
– something that we do not observe. Therefore, such a behavior is only feasible in 
presence of two binding sites for c-di-GMP per a DgcB monomer, an independent 
one and one that binds only in combination with the other. As mentioned before, 
besides using the modified primary I-site for this task, DgcB could utilize R200 as the 
secondary I-site. It is localized in the 0-helix, one turn in front of the topologically 
analogous R313 of PleD’s secondary I-site (IS,DGC) (16). This arginine could cross-
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link with the c-di-GMP loaded primary I-site leading to formation of tetramers. To 
prove this possibility mutagenesis might be the appropriate technique. 
Elongation of the spheroid dimension ratio of DgcB tetramers in comparison to the 
dimeric species (Table 3) indicates an antiparallel arrangement of the dimers in a two-
fold symmetric tetramer. Two distinct extremes are hereby imaginable. The DgcB 
dimers could form tetramers interacting solely via the cross-linking c-di-GMP 
molecules (kissing complex) or via extended protein-protein contacts in addition to 
the c-di-GMP cross-linking (hugging complex). The later extreme is in agreement 
with the very low tetramerization KD of c-di-GMP loaded DgcB and is therefore a 
more probable one for DgcB. A DGC with such an arrangement has been observed 
before. The dimeric WspR forms in its crystal structure intercalated tetramers (17), 
but is stated by the authors as a crystal artifact. Similar arrangement might be utilized 
by DgcB in the c-di-GMP loaded state. 
Intermolecular cross-linking of proteins via c-di-GMP opens new possibilities in the 
field of ‘c-di-GMP-signaling’. Although c-di-GMP is known to be involved in 
regulation of several critical processes as virulence, biofilm formation and cell cycle 
progression (5,32,36) the amount of the identified c-di-GMP targets is rare, including 
PilZ domain proteins and riboswitches (11,13). One of the downstream effects of the 
second messenger c-di-GMP could be homo- and heteromolecular cross-linking of 
proteins modulating so their activity. Finding of such interactions with common 
techniques is a rather difficult task and might represent the reason for the little 
number of known downstream targets of c-di-GMP. 
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Figure legends 
 
Figure 1. Partial sequence alignment of DgcA and DgcB with diguanylate cyclases 
PleD and WspR,  
(A) Schematic representation of the domain architecture of DgcA (Uniprot: Q9A3B9) 
and DgcB (Uniprot: Q9A776). The GGDEF domains are shown in green and the N-
terminal in yellow. 
(B) Truncated sequence alignments of GGDEF domains of DgcA DgcB and PleD 
from C. crescentus and WspR from P. aeruginosa [by CLUSTALX (37)]. The 
consensus sequence motif of the active site, GGDEF, is shaded in blue. The primary 
I-site, composed of the RxxD motif and in case of PleD of R390, are shaded in red 
and brown, respectively. Arginines in the α0-helix, which are or might be part of the 
secondary I-site, are shaded in green. Secondary structure elements of PleD derived 
from the crystal structure are shown above the sequence alignment. Arrows and bars 
represent β-strands and α-helices, respectively.  
 
Figure 2. Time course of c-di-GMP production 
C-di-GMP production of DgcA (A) and DgcB (B) in presence (circles) and absence 
(triangles) of the PDE YahA and of ∆DgcA (A) in presence of YahA (diamonds). 
 
Figure 3. Inhibition of DgcB by c-di-GMP 
Plot of specific activity of DgcB at various c-di-GMP concentrations. The 
experimental data (diamonds) were fitted with an exponential decay function 
(continuous line) yielding an IC50 of 20 µM at a protein concentration of 26 µM. 
 
Figure 4. Binding of c-di-GMP to an allosteric site of DgcB 
(A) Raw ITC data with 120 µM c-di-GMP titrated into 5 µM DgcB at 25 °C. (B) 
Integrated peaks of c-di-GMP titration to DgcB (circles) and to DgcB pre-incubated 
with 200 µM GTPαS (rectangles). (C) Integrated peaks of GTPαS titration to DgcB 
(rectangles) and to DgcB pre-incubated with 200 µM c-di-GMP (circles). Fits 
representing the binding of the ligands are shown as solid lines. 
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Figure 5. SPR experiment representing c-di-GMP steady-state binding to immobilized 
DgcB 
Representation of a sensorgram plot showing steady-state binding of different c-di-
GMP concentrations (1.30, 1.00, 0.78 and 0.65 µM shown in black, red, green and 
blue, respectively) to DgcB, which is immobilized on a NTA chip. The analyte 
samples were injected for six minutes and the dissociation was recorded for seven 
minutes. The steady-state was reached approximately 200 s after c-di-GMP injection 
initiation. 
 
Figure 6. Scatchard plot analysis of the SPR steady-state experiment 
Scatchard plot of c-di-GMP binding to immobilized DgcB. Req are measured RU 
values 250 seconds after the injection initiation. For the calculation of the Req/canalyte 
values nominal (A) and dimer (B) concentrations of c-di-GMP were used assuming a 
c-di-GMP dimerization KD of 50 µM. The slope of the resulting straight is equal to 
the negative value of KA and the intercept to KA × Rmax. 
 
Figure 7. Kinetic analysis of c-di-GMP binding to immobilized DgcB 
Binding sensorgrams of c-di-GMP to DgcB. C-di-GMP was used at nominal 
concentrations of 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78 and 0.39 µM. (A) Fits of the 
sensorgrams using the nominal c-di-GMP concentrations and the ‘Heterogeneous 
ligand – parallel reactions’ or the ‘Bivalent analyte’ fitting algorithm of the 
BIAevaluation software (green and red stripped lines, respectively). (B) Fits of the 
same sensorgrams using a simple ‘1:1 binding with drifting baseline’ algorithm of the 
BIAevaluation software and the calculated concentrations of c-di-GMP dimers (see 
Materials&Methods) assuming a dimerization KD of 50 or 10 µM (green and red 
stripped lines, respectively). 
 Residuals of the fits are shown in the lower panels (C, D, E, F). 
 
Figure 8. Analysis of DgcB oligomerization state by SEC MALS 
SEC MALS experiments were performed with DgcB at initial concentrations of 26 
(A, B), 390 (C, D) and 676 µM (E) with apo-DgcB (A, C, E) and c-di-GMP pre-
incubated DgcB (B, D). The analysis includes monitoring of the UV signal (red 
stripped line), differential refractive index signal (black dotted line) and the light 
scattering signal (black line) in the range between the column void volume (V0) and 
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the total column volume (Vt). Blue lines indicate the calculated molecular weights of 
both peaks. 
 
Figure 9. Sedimentation equilibrium runs of apo and c-di-GMP loaded DgcB 
Representative plots of the SE runs of apo (red symbols) and c-di-GMP loaded (blue 
symbols) DgcB detecting the absorbance at 253 (A) and 280 nm (B), respectively. 
The black lines represent the global fits. Corresponding plots of the residuals are 
shown in the upper part of the figure. 
 
Figure 10. Sedimentation coefficient distribution plot for DgcB 
Sedimentation velocity analytical ultracentrifugation experiments were performed 
with DgcB (26 µM) in absence (stripped line) and presence of c-di-GMP (60µM) 
(full line). 
 
Supplemental figure 1. BIACORE analysis of c-di-GMP binding to DgcA and 
∆DgcA 
Both His6-tagged proteins were immobilized to two different channels of an NTA-
Chip (GE Healthcare). Injections of c-di-GMP (31.25, 62.5, 125, 250, 500 µM, 
respectively) were applied to the channels with immobilized protein as well as to a 
reference channel. Due to a constant drift in the base line and lack of an appropriate 
regeneration condition for the immobilized protein c-di-GMP was injected in kinetic 
titration series (38). Sensorgrams, which are subtracted by the reference channel 
signal, show reproducible binding of c-di-GMP to DgcA (red line) and ∆DgcA (black 
and green lines). Neither the binding constants nor the thermodynamic parameters 
could be deduced from these experiments. The analysis failed due to a combination of 
erroneous factors: a complex drifting base line and a c-di-GMP solution containing 
additional, unknown ingredients, resulting in a solution effect that couldn’t be 
compensated for. 
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Table 1: SPR derived kinetic and thermodynamic rate constants 
 
SPR 
equilibrium 
experiment 
(Scatchard) 
SPR kinetics experiments                                          
(1:1 fitting algorithm) Fit relevant                  
c-di-GMP species 
binding KD                                
of c-di-GMP to DgcB (M) kon (M
-1
 s-1) koff (s-1) χ2 
monomeric 
(nominal [c-di-GMP]) 1.7×10
-6
 2.4×10-7 8.5×103 2.1×10-3 1.3 
dimeric 
(c-di-GMP dimerization 
KD = 10 µM) 
3.6×10-8 2.8×10-8 1.2×105 3.3×10-3 0.5 
dimeric 
(c-di-GMP dimerization 
KD = 50 µM) 
7.8×10-9 8.1×10-9 4.4×105 3.6×10-3 0.5 
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Table 2: SEC-MALS results DgcB in absence and presence of c-di-GMP       
   (n.d. not detected) 
 
Initial DgcB 
concentration 
(M) 
Incubation with               
c-di-GMP (µM)  Peak 1 Peak 2 
26 -   n.d. 
  peak limits (ml) 12.81 – 14.02  
  MW (kDa) 71.7 ± 0.6  
  polydispersity (MW / MN) 1.000 ± 0.008  
  max. peak concentration (µM) 3.2  
26 + 80     
  peak limits (ml) 12.92 – 13.76 10.12 – 12.17 
  MW (kDa) 72.5 ± 0.7 124.6 ± 12.5 
  polydispersity (MW / MN) 1.000 ± 0.010 1.052 ± 0.142 
  max. peak concentration (µM) 2.4 0.2 
390 -    
  peak limits (ml) 13.21 – 13.58 12.15 – 12.63 
  MW (kDa) 78.2 ± 0.3 104.2 ± 0.5 
  polydispersity (MW / MN) 1.002 ± 0.010 1.001 ± 0.009 
  max. peak concentration (µM) 21.8 27.8 
390 + 1000  n.d.  
  peak limits (ml)  11.66 – 12.33 
  MW (kDa)  139.0 ± 0.1 
  polydispersity (MW / MN)  1.002 ± 0.002 
  max. peak concentration (µM)  29.4 
676 -    
  peak limits (ml) 13.28 – 13.79 11.95 – 12.46 
  MW (kDa) 73.8 ± 0.2 121.7 ± 0.4 
  polydispersity (MW / MN) 1.000 ± 0.004 1.003 ± 0.007 
  max. peak concentration (µM) 50.5 32.5 
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Table 3: SE-AUC results of the DgcB ± c-di-GMP runs 
 
 
 
 
 
 
Table 4: SV-AUC results of the DgcB ± c-di-GMP runs 
 
abundance [%] 
sample 
residual protein  
concentration [µM] dimer tetramer 
KD of tetramer. 
[µM] 
DgcB 7.07 98.5 1.2 571 
DgcB +              
c-di-GMP 2.56 9.1 83.8 0.02 
Ratio of 
spherical axes 
(a/b) sample quaternary state 
abundance 
[%] 
S 
[10-13 s] 
RH  
[nm] 
D 
[10-7 
cm2/s] 
f/f0 
oblate prolate 
DgcB dimer 98.4 3.81 3.8 4.167 1.35 4.24 4.52 
dimer 8.4 3.55 4.1 3.882 1.45 5.57 6.05 
tetramer 73.3 5.21 5.6 2.849 1.56 7.27 8.04 
DgcB 
+ 
c-di-GMP higher 
aggregate 13.0 shoulder      
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III CONCLUSIONS AND PERSPECTIVES 
 
The DGCs are known to be enzymatically active as dimers (43). This work has shown 
that isolated GGDEF domains are not able to form dimers and that therefore the so-
called ‘stand-alone’ DGCs use their N-terminal segments for dimerization. 
Hereby, two different kinds of ‘stand-alone’ DGCs were identified. The permanently 
dimeric and active ‘steady-state keepers’ like DgcA produce c-di-GMP independently 
of any environmental cues sustaining a constant c-di-GMP level. The enzymatic 
activity of these proteins is limited solely by the allosteric product inhibition. The 
dimeric ‘signal amplifiers’ like DgcB, on the other hand, use their N-terminal 
dimerization segments/domains additionally for modulation of their enzymatic 
activity in response to environmental cues. Future investigations must aim at the 
identification and the characterization of these regulatory dimerization domains in 
order to get insights into the upstream signaling cascade components. 
To use the dimerization process itself as a regulatory mechanism is the concern of 
several DGCs, e.g. the ones bearing N-terminal Rec-domains. The crystal structure of 
BeF3¯ •Mg2+ activated PleD is one of the first structures showing a full-length 
response regulator in its activated state. Comparison with the structure of non-
activated PleD (22) resulted in the elucidation of the molecular mechanisms of the 
dimerization process. Additionally, the formation of a two-fold symmetric, charged 
pocket at the (Rec1-Rec2)2 stem interface probably explains the role of the non-
phosphorylatable Rec2 domain in PleD and might represent the long-sought ‘pole-
localization’-signal for PleD and other Rec1-Rec2-GGDEF domain proteins. 
Besides giving insights in the substrate binding mode of the DGCs, the obtained 
crystal structures of activated PleD shed light on the catalytic mechanism of DGCs. In 
combination with biochemical data the structures verified the ‘two-metal assisted’ 
catalysis mechanism for the DGCs. In future, combination of mutational and 
structural examinations should prove the relevance of the proposed mechanistic 
aspects for the catalysis: (I) the occurrence of conformational changes during the 
formation of the dimeric active site in the GGDEF domains; (II) the crucial role of the 
GGDEF sequence motif’s glutamate in the process of quasi simultaneous 
phosphodiester-bond formation as well as in the process of the product-release. 
The most-inspiring scientific results derive from the investigations concerning the 
allosteric product inhibition mechanism. The crystal structures of activated PleD 
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revealed a new, c-di-GMP dimer dependent domain-cross-linking mode that is 
generally applicable to DGCs, involving in the process merely the GGDEF domains. 
It turned out that the successful inhibition of the DGC PleD relies on the presence of 
primary- and secondary I-sites, whereas the initial binding of c-di-GMP depends 
mainly on the primary I-site. 
The minimal composition of the primary I-site stays yet unclear. Whereas PleD was 
shown to need both the RxxD motif and the R390 in order to bind c-di-GMP, other 
DGCs don’t seem to utilize the arginine at an analogue position to PleD’s R390 for 
the binding process. Further complication of the c-di-GMP binding process poses the 
allosteric inhibition of DgcB that has a degenerated RxxD motif. Combination of 
mutagenesis and structural elucidation of the c-di-GMP-DgcB complex will be an 
imperative step in the global understanding of the allosteric product inhibition. 
Finally, the shown ability of c-di-GMP to cross-link proteins, intramolecularly in 
PleD and intermolecularly in DgcB, opens new possibilities for the second messenger 
in response-modulation of the signal transduction components. If c-di-GMP turns out 
to exert its role in cross-linking downstream effectors leading subsequently to a 
specific cellular response, it will be inevitable to combine microbiological, 
biochemical, biophysical (SPR) and structural (x-ray crystallography and electron 
microscopy) techniques to elucidate the underlying mechanisms. 
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